Nabriva Therapeutics (NBRVF) 10-K 24 Mar 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Mar. 01, 2017	Jun. 30, 2016
Document and Entity Information
Entity Registrant Name	Nabriva Therapeutics AG
Entity Central Index Key	1,641,640
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Public Float			$ 74.7
Entity Common Stock, Shares Outstanding		2,719,851
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 32,778	$ 36,446
Short-term investments	51,106	74,994
Other receivables	5,561	4,195
Prepaid expenses	1,176	610
Total current assets	90,621	116,245
Property, plant and equipment, net	519	417
Intangible assets, net	270	3
Long-term receivables	420	430
Deferred tax assets	1,410	616
Total assets	93,240	117,711
Current liabilities:
Accounts payable	2,551	2,928
Accrued expense and other current liabilities	13,308	5,823
Income taxes payable	18	170
Total current liabilities	15,877	8,921
Other non-current liabilities	107	84
Total liabilities	15,984	9,005
Commitments and contingencies (Note 21)
Mezzanine equity:
Investment from silent partnership
Total mezzanine equity
Stockholders' Equity:
Common stock - no par value; 912,920 and 1,389,786 shares authorized at December 31, 2015 and 2016; 2,116,778 and 2,719,695 shares issued and outstanding at December 31, 2015 and 2016, respectively	2,939	2,407
Treasury shares -- at cost; 2,819 shares at December 31, 2015 and 0 shares at December 31, 2016, respectively		(25)
Additional paid in capital	279,149	273,921
Accumulated other comprehensive income (loss)	10	3,829
Accumulated deficit	(204,842)	(171,426)
Total stockholders' equity	77,256	108,706
Total liabilities and stockholders' equity	$ 93,240	$ 117,711

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Consolidated Balance Sheets
Common stock, no par value	$ 0	$ 0
Common stock, authorized shares	1,389,786	912,920
Common stock issued shares	2,719,695	2,116,778
Common stock, outstanding shares	2,719,695	2,116,778
Treasury shares, shares	0	2,819

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenues:
Research premium and grant revenue	$ 6,482	$ 3,767	$ 2,398
Operating expenses:
Research and development	(47,994)	(23,604)	(9,355)
General and administrative	(13,535)	(7,921)	(3,739)
Total operating expenses	(61,529)	(31,525)	(13,094)
Loss from operations	(55,047)	(27,758)	(10,696)
Other income (expense):
Other income (expense), net	(783)	2,427	(524)
Interest income	343	14	2
Interest expense	(75)	(22,092)	(2,910)
Loss before income taxes	(55,562)	(47,409)	(14,128)
Income tax (expense) benefit	672	445	(94)
Net loss	(54,890)	(46,964)	(14,222)
Other comprehensive income (loss), net of tax
Exchange differences on translating foreign operations		2,026	3,374
Unrealized losses on available-for-sale financial assets	(18)	(68)
Reclassification to net income	68
Other comprehensive income (loss), net of tax	50	1,958	3,374
Comprehensive loss	$ (54,840)	$ (45,006)	$ (10,848)
Loss per share
Basic (in dollars per share)	$ (25.56)	$ (48.03)	$ (44.39)
Diluted (in dollars per share)	$ (25.56)	$ (48.03)	$ (44.39)
Weighted average number of shares:
Basic (in shares)	2,147,832	1,058,395	324,703
Diluted (in shares)	2,147,832	1,058,395	324,703

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Common StockApril 2015 Financing	Common StockKreos Loan 2014Call Options	Common StockOptions	Common Stock	Treasury SharesOptions	Treasury Shares	Additional paid in capitalIPO	Additional paid in capitalApril 2015 Financing	Additional paid in capitalDecember 2016 Financing	Additional paid in capitalKreos Loan 2014Call Options	Additional paid in capitalOptions	Additional paid in capital	Accumulated other comprehensive income (loss)	Accumulated deficit	IPO	April 2015 Financing	December 2016 Financing	Kreos Loan 2014Call Options	Options	Total
Stockholders' equity, beginning balance at Dec. 31, 2013				$ 432		$ (25)						$ 88,643	$ (1,503)	$ (106,173)						$ (18,626)
Stockholders' equity, beginning balance (in shares) at Dec. 31, 2013				328,000		3,000
Consolidated Statements of Changes in Stockholders' Equity (Deficit)
Stock based compensation expense												90								90
Beneficial conversion feature of silent partnership								$ 36								$ 36
Adjustment to redemption value of silent partnership														(192)						(192)
Beneficial conversion feature of convertible loans												526								526
Cumulative translation adjustment, net of tax													3,374							3,374
Net loss														(14,222)						(14,222)
Stockholders' equity, ending balance at Dec. 31, 2014				$ 432		$ (25)						89,295	1,871	(120,587)						(29,014)
Stockholders' equity, ending balance (in shares) at Dec. 31, 2014				328,000		3,000
Investment from Silent Partnership
Issuance of Silent Partnership Agreement, net of transaction fees																				552
Beneficial conversion feature of silent partnership																				(36)
Adjustment to redemption value of silent partnership																				192
Cumulative translation adjustment, net of tax																				(74)
Carrying amount as of end of year at Dec. 31, 2014																				634
Total Equity, beginning balance at Dec. 31, 2013																				(18,626)
Increase (Decrease) in Combined Equity [Rollforward]
Cumulative translation adjustment, net of tax																				3,300
Total Equity, ending balance at Dec. 31, 2014																				(28,380)
Consolidated Statements of Changes in Stockholders' Equity (Deficit)
Issuance of stock	$ 17			$ 1,725				2,733				149,218				2,750				150,943
Number of shares sold	15,000			1,563,000
Conversion of convertible securities				$ 222								22,519								22,741
Shares issued in exchange for the conversion of convertible loans and silent partnerships investments				204,000
Exercise of options		$ 10	$ 1							$ 1,420	$ 124							$ 1,430	$ 125
Exercise of options (in shares)		9,000	1,000
Equity transaction costs							$ (13,616)	$ (1,313)							$ (13,616)	(1,313)
Stock based compensation expense												1,249								1,249
Beneficial conversion feature of silent partnership												2,561								2,561
Adjustment to redemption value of silent partnership														(3,875)						(3,875)
Beneficial conversion feature of convertible loans												18,993								18,993
Extension of CLA repayment date - Modification												738								738
Unrealized gain (loss) on available-for-sale financial assets													(68)							(68)
Cumulative translation adjustment, net of tax													2,026							2,026
Net loss														(46,964)						(46,964)
Stockholders' equity, ending balance at Dec. 31, 2015				$ 2,407		$ (25)						273,921	3,829	(171,426)						$ 108,706
Stockholders' equity, ending balance (in shares) at Dec. 31, 2015				2,120,000		3,000														2,116,778
Investment from Silent Partnership
Issuance of Silent Partnership Agreement, net of transaction fees																				$ 962
Contribution of silent partnerships																$ (2,750)				(2,750)
Beneficial conversion feature of silent partnership																				(2,561)
Adjustment to redemption value of silent partnership																				3,875
Cumulative translation adjustment, net of tax																				(160)
Carrying amount as of end of year at Dec. 31, 2015
Increase (Decrease) in Combined Equity [Rollforward]
Cumulative translation adjustment, net of tax																				1,866
Change in functional currency				$ (99)		$ 3						(17,509)	(3,869)	21,474
Stockholders' equity, adjusted balance at Jan. 01, 2016				$ 2,308		$ (22)						256,412	(40)	(149,952)						108,706
Stockholders' equity, ending balance (in shares) at Jan. 01, 2016				2,120,000		3,000
Stockholders' equity, beginning balance at Dec. 31, 2015				$ 2,407		$ (25)						273,921	3,829	(171,426)						$ 108,706
Stockholders' equity, beginning balance (in shares) at Dec. 31, 2015				2,120,000		3,000														2,116,778
Consolidated Statements of Changes in Stockholders' Equity (Deficit)
Issuance of stock				$ 618								24,204								$ 24,822
Number of shares sold				588,000
Exercise of options			$ 13		$ 22						$ 2,695								$ 2,730
Exercise of options (in shares)			12,000		(3,000)
Equity transaction costs									$ (4,247)								$ (4,247)
Stock based compensation expense												85								85
Unrealized gain (loss) on available-for-sale financial assets													(18)							(18)
Reclassification to net income													68							68
Net loss														(54,890)						(54,890)
Stockholders' equity, ending balance at Dec. 31, 2016				$ 2,939								$ 279,149	$ 10	$ (204,842)						$ 77,256
Stockholders' equity, ending balance (in shares) at Dec. 31, 2016				2,720,000																2,719,695
Carrying amount as of beginning of year at Dec. 31, 2015
Carrying amount as of end of year at Dec. 31, 2016
Total Equity, ending balance at Dec. 31, 2016																				$ 77,256

Consolidated Statements of Cash

Consolidated Statements of Cash Flows $ in Thousands, € in Millions	12 Months Ended
	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Cash flows from operating activities
Net income (loss)	$ (54,890)	$ (46,964)	$ (14,222)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Non-cash other income, net		144	663
Non-cash interest income	(52)	(1)
Non-cash interest expense	35	21,465	1,892
Depreciation and amortisation expense	233	153	166
Stock-based compensation	2,545	1,351	96
Deferred income taxes	(794)	(627)	11
Other, net	1	(5)	1
Changes in operating assets and liabilities:
Changes in long-term receivables	10	(71)	(38)
Changes in accounts receivables	(1,932)	(3,181)	(647)
Changes in accounts payable	(383)	2,651	(118)
Changes in accrued expenses and other liabilities	6,034	3,971	684
Changes in other non-current liabilities	24	9	27
Changes in income tax liabilities	(152)	(753)	78
Net cash used in operating activities	(49,321)	(21,858)	(11,407)
Cash flows from investing activities
Purchases of plant and equipment and intangible assets	(603)	(216)	(90)
Purchases of available-for-sale securities	(57,035)	(30,603)
Purchases of term deposits	(10)	(45,885)
Proceeds from sales of property, plant and equipment			3
Proceeds from maturities of term deposits	45,000
Proceeds from sales of available-for-sale securities	36,000
Net cash (used in) provided by investing activities	23,352	(76,704)	(87)
Cash flows from financing activities
Proceeds from initial public offering		106,088
Proceeds from April 2015 financing		44,836
Proceeds from December 2016 financing	24,822
Other proceeds from shareholders		29
Proceeds from silent partnership		943	536
Proceeds from long-term borrowings			6,171
Proceeds from exercise of stock options	269	5
Proceeds from convertible loans		3,436	4,716
Repayments of participation rights		(6)
Repayments of long-term borrowings		(7,383)	(2,325)
Equity transaction costs	(2,790)	(14,930)
Net cash provided by financing activities	22,301	133,018	9,098
Effects of foreign currency translation on cash and cash equivalents		(160)	(411)
Net (decrease) increase in cash and cash equivalents	(3,668)	34,296	(2,807)
Cash and cash equivalents at beginning of period	36,446	2,150	4,957
Cash and cash equivalents at end of period	32,778	36,446	2,150
Supplemental disclosures of cash flow information:
Interest paid	(41)	(1,057)	(553)
Taxes paid	$ (867)	$ (939)	$ (5)

Organization and Business Activ

Organization and Business Activities	12 Months Ended
	Dec. 31, 2016
Organization and Business Activities
Organization and Business Activities	1. Organization and Business Activities Nabriva Therapeutics AG, together with its 100% owned and consolidated U.S. subsidiary Nabriva Therapeutics US, Inc., (“Nabriva”, “the Group” or the “Company”) is a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. Nabriva was incorporated in Austria as a spin-off from Sandoz GmbH in October 2005 and commenced operations in February 2006. The Company’s headquarters are at Leberstrasse 20, A-1110 Vienna. Nabriva Therapeutics US, Inc. was founded and began operations in the United States in August 2014. Liquidity Since its inception, the Company incurred net losses and generated negative cash flows from its operations. To date, it has financed its operations through the sale of equity securities, including its initial public offering of ADSs and private placements of its common shares, convertible debt financings and research and development support from governmental grants and loans. As of December 31, 2016, the Company had cash and cash equivalents and short term investments of $83.9 million. On December 19, 2016, the Company completed a rights offering and a related underwritten offering for the sale of an aggregate of 588,127 common shares resulting in aggregate gross proceeds of approximately $24.8 million and net proceeds to us of approximately $20.6 million, after deducting underwriting fees and offering expenses. On September 23, 2015 the Company completed its initial public offering on the NASDAQ Global Market issuing 9,000,000 ADSs at a price to the public of $10.25 per ADS, representing 900,000 of its common shares. Each ADS represents one tenth of a common share. On September 30, 2015 the underwriters of its initial public offering exercised in full their over-allotment option to purchase an additional 1,350,000 ADSs, representing 135,000 common shares, at the initial public offering price of $10.25 per ADS, less underwriting discounts. Including the over-allotment ADSs, the Company sold an aggregate of 10,350,000 ADSs representing 1,035,000 common shares, in its initial public offering, which resulted in gross proceeds of approximately $106.1 million and net proceeds to the Company of approximately $92.4 million, after deducting underwriting discounts and offering expenses. In connection with the Company’s April 2015 financing, it sold 730,162 common shares with contractual preference rights under a shareholders agreement, including the sale of 511,188 common shares at a price per share of €82.35 ($87.71) for €42.1 million ($44.8 million) in cash consideration and the sale of 218,974 common shares in exchange for certain contributions in-kind consisting of the conversion of outstanding convertible loans and silent partnership interests. The Company also agreed to sell a second tranche of common shares with contractual preference rights under the shareholders agreement to the investors in its April 2015 financing at their option for an aggregate purchase price of $70.0 million if the Company did not complete a public offering in the United States within specified parameters or by a specified date. Upon the closing of its initial public offering and the issuance of the shares for nominal value in satisfaction of the preferred dividend rights, all contractual preference rights under the shareholders agreement terminated. Between 2011 and 2015 the Company entered into five convertible loan agreements with certain of its shareholders for proceeds in the aggregate amount of $18.2 million. All outstanding convertible loans converted into common shares with contractual preference rights under the shareholders agreement in connection with its April 2015 financing. The Company entered into silent partnership agreements with certain of its shareholders for aggregate proceeds of $0.5 million in the second quarter of 2014 and $0.9 million in the first quarter of 2015. These agreements have terminated and the related claims for repayment were converted into common shares with contractual preference rights under the shareholders agreement in connection with its April 2015 financing. Also during the second quarter of 2014, the Company entered into a €5.0 million ($6.6 million) loan agreement with Kreos that resulted in net proceeds of $6.2 million after deduction of the initial interest and principal payments and transaction costs at closing. In connection with the loan agreement, the Company granted Kreos Capital IV (Expert Fund) Limited a warrant to purchase its common shares with contractual preference rights under the shareholders agreement, which Kreos Capital IV (Expert Fund) Limited has exercised in full. As collateral for the loan, the Company pledged its intellectual property, fixed assets exceeding a book value of €1,000 the receivables related to the research premium and our bank accounts. In July 2015, Kreos Capital IV (UK) Limited agreed to release the Company from the pledge of its intellectual property upon the closing of its initial public offering. The Company prepaid the Kreos loan in accordance with the terms of the loan agreement in November 2015. The Company expect that its existing cash, cash equivalents and short-term investments will be sufficient to enable it to fund its operating expenses and capital expenditure requirements at least into the second quarter of 2018 and to obtain top-line data for both its Phase 3 clinical trials of lefamulin. The Company has based this estimate on assumptions that may prove to be wrong, and the Company could use its capital resources sooner than it currently expects. This estimate assumes, among other things, that the Company does not obtain any additional funding through grants and clinical trial support, collaboration agreements or debt financings. If the Company is unable to raise capital when needed or on attractive terms, it could be forced to delay, reduce or eliminate its research and development programs or any future commercialization effort.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise noted. Basis of Preparation The consolidated financial statements of Nabriva Therapeutics AG have been prepared on a historical cost basis with the exception of certain items such as available-for-sale financial assets or some financial liabilities (debt derivatives resulting from conversion rights and options) which are shown at fair value. The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and US Securities and Exchange Commission (“SEC”) regulations for annual reporting. The preparation of financial statements in conformity with US GAAP requires the use of certain critical accounting estimates. It requires management to exercise its judgment in the process of applying the Company’s accounting policies. Recent Accounting Pronouncements At the time of authorization of these consolidated financial statements for publication, a number of revisions, amendments and interpretations had already been published by the FASB. None of these are expected to have a significant effect on the consolidated financial statements of the Company, except the following set out below: · In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers , an updated standard on revenue recognition. ASU 2014-09 provides enhancements to the quality and consistency of how revenue is reported by companies while also improving comparability in the financial statements of companies reporting using International Financial Reporting Standards or GAAP. The main purpose of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which a company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively and improve guidance for multiple-element arrangements. In July 2015, the FASB voted to approve a one-year deferral of the effective date of ASU 2014-09, which will be effective for the Company in the first quarter of fiscal year 2018 and may be applied on a full retrospective or modified retrospective approach. ASU 2014-09 will have no impact on the Company until it begins to generate revenue. · In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern . ASU 2014-16 explicitly requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management will assess if there is substantial doubt about an entity’s ability to continue as a going concern within one year after the issuance date. Management will consider relevant conditions that are known, and reasonably knowable, at the issuance date. Substantial doubt exists if it is probable that the entity will be unable to meet its obligations within one year after the issuance date. Disclosures will be required if conditions give rise to substantial doubt. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Early adoption is permitted. The Company has performed its assessment and determined that it has sufficient financial reasourses to meet its cash requirements into the second quarter of 2018. · In November 2015, the FASB issued ASU 2015-17, Income Taxes: Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the balance sheet classification of deferred taxes and requires that all deferred taxes be presented as noncurrent. ASU 2015-17 is effective for fiscal years beginning after December 15, 2016 with early adoption permitted. The adoption of this update is not expected to have a material effect on the Company’s financial statements. · In January 2016, FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities . ASU 2016-01 requires equity investments to be measured at fair value with changes in fair value recognized in net income; simplifies the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment; eliminates the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet; requires public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes; requires an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments; requires separate presentation of financial assets and financial liabilities by measurement category and form of financial assets on the balance sheet or the accompanying notes to the financial statements and clarifies that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets. ASU 2016-01 is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the impact that ASU 2016-01 will have on its financial statements and related disclosures. · In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods, with early adoption permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact that the standard will have on its financial statements and related disclosures. · In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting , which provides for simplification of certain aspects of employee share-based payment accounting including income taxes, classification of awards as either equity or liabilities, accounting for forfeitures and classification on the statement of cash flows. ASU 2016-09 will be effective for the Company in the first quarter of 2017 and will be applied either prospectively, retrospectively or using a modified retrospective transition approach depending on the area covered in this update. The Company is currently evaluating the impact that the standard will have on its financial statements and related disclosures. · In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) (“ASU 2016-08”), in April 2016 issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing (“ASU 2016-10”), and in May 2016, issued ASU 2016-11, Revenue Recognition (Topic 605) and Derivatives and Hedging (Topic 815): Rescission of SEC Guidance Because of Accounting Standards Updates 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 EITF Meeting (“ASU 2016-11”) . ASU 2016-08 clarifies principal versus agent considerations relating to when another party, along with the entity, is involved in providing a good or service to a customer. ASU 2016-08 requires an entity to determine whether the nature of its promise is to provide a good or service to a customer, or to arrange for the good or service to be provided to the customer by the other party. This determination is based upon whether the entity controls the good or service before it is transferred to the customer. When the entity that satisfies a performance obligation is the principal, the entity recognizes the gross amount of consideration as revenue. When the entity that satisfies the performance obligation is the agent, it recognizes the amount of any fee or commission as revenue. ASU 2016-10 clarifies the guidance in Topic 606 for identifying performance obligations in a contract as well as the implementation guidance pertaining to revenue recognition related to licensing arrangements. ASU 2016-11 rescinds several SEC Staff Announcements that are codified in Topic 605, including, among other items, guidance relating to accounting for consideration given by a vendor to a customer, as well as accounting for shipping and handling fees and freight services. The Company is currently evaluating the impacts of this standard on its financial statements and anticipates no significant effects when the standard is adoped as of the effective date. · In May 2016, the FASB also issued ASU 2016-12, Revenue from Contracts with Customers - Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”), which provides clarification on certain topics within ASU 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), including assessing collectability, presentation of sales taxes, the measurement date for non-cash consideration and completed contracts at transition, as well as providing a practical expedient for contract modifications at transition. The effective date and transition requirements for the amendments in ASU 2016-08, ASU 2016-10 and ASU 2016-12 are the same as the effective date and transition requirements of ASU 2014-09, which is effective for fiscal years, and for interim periods within those years, beginning after December 15, 2017. The Company is currently evaluating the impacts of this standard on its financial statements and anticipates no significant effects when the standard is adoped as of the effective date. · In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments . The amendments in this ASU introduce clarifications to the presentation of certain cash receipts and cash payments in the statement of cash flows. The primary updates include additions and clarifications of the classification of cash flows related to certain debt repayment activities, contingent consideration payments related to business combinations, proceeds from insurance policies, distributions from equity method investees and cash flows related to securitized receivables. This update is effective for annual periods beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption of this ASU is permitted, including in interim periods. The ASU requires retrospective application to all prior periods presented upon adoption. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its cash flows and/or disclosures, however, the Company does not anticipate that the new guidance will have a significant impact on its financial statements and related disclosures. · In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash . ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The amendments in this ASU are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company does not expect the adoption of the amendments to have a material effect on its financial statements and related disclosures. Consolidation The consolidated financial statements include the financial information of Nabriva Therapeutics AG and its 100% owned subsidiary, Nabriva Therapeutics US, Inc. a Delaware corporation, founded in August 2014. All intercompany balances and transactions are eliminated. Subsequent Events Material subsequent events are evaluated and disclosed through the report issuance date. Segment Reporting The Company comprises a single operating and reportable segment engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The management team is the chief operating decision maker, and it reviews the consolidated operating results regularly to make decisions about the allocation of the Company’s resources, and to assess overall performance. Foreign Currency Translation Functional and presentation currency Effective January 1, 2016, the Company’s functional and reporting currency changed to the U.S. dollar (“USD”). Prior to January 1, 2016, the consolidated financial statements were presented in euro (“€”), which was the Company’s functional and presentation currency. With the expansion of Nabriva’s operations to the United States, the Company’s assets, liabilities, revenues and expenses are expected to be predominantly denominated in USD, and accordingly, the use of USD to measure and report the Company’s financial performance and financial position was considered to be more appropriate. The impact of the currency translation up to January 1, 2016 is recorded in accumulated other comprehensive income (loss). Upon the change in functional currency on January 1, 2016, all assets and liabilities of the Company’s operations were translated from their euro functional currency into USD using the exchange rates in effect on the balance sheet date, equity was translated at the historical rates and revenues, expenses, and cash flows were translated at the average rates during the reporting period presented. The resulting translation adjustments are reported under comprehensive income (loss) as a separate component of equity. Transactions and balances In preparing the financial statements of each individual group entity, transactions in currencies other than the entity’s functional currency (foreign currencies) are recognized at the exchange rates prevailing at the dates of the transactions. Foreign currency exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the consolidated statement of comprehensive income (loss). Research Premium and Grant Revenue Grant revenue comprises (a) the research premium from the Austrian government, (b) grants received from the Vienna Center for Innovation and Technology ( Zentrum für Innovation, or ZIT ) and the Vienna Business Promotion Fund ( Wiener Wirtschaftsförderungsfonds, or WWFF ) and (c) the benefit of government loans at below-market interest rates. Please refer to Note 3 for further details on all forms of grant revenue. The research premium was calculated as 10% of a specified research and development cost base for the years ended December 31, 2015 and December 31, 2014. For the year ended December 31, 2016, the research premium is calculated as 12% of a specified research and development cost base. It is recognized to the extent the research and development expenses have been incurred. The WWFF grant is paid out through the landlord in the form of a monthly reduction in lease payments and is recognized over the period from grant date in March 2010 until end of the lease termination waiver term in December 2017. The ZIT grants are provided to support specific research projects and are recognized according to the progress of the respective project. All grants are non-refundable as long as the conditions of the grant are met. Nabriva is and has been in full compliance with the conditions of the grants and all related regulations. The benefit of a government loan at a below-market rate of interest is treated as a government grant. The benefit due to the difference between the market rate of interest and the rate of interest charged by the governmental organization is measured as the difference between the initial carrying value of the loan determined and the proceeds received. This benefit is deferred, and recognized through profit and loss over the term of the corresponding liabilities. Research and Development Expenses All research and development costs are expensed as incurred. The following costs, in particular by their nature, constitute research and development expenses: direct personnel and material costs, related overheads for internal or external technology, engineering and other departments that provide services; costs for experimental and pilot facilities (including depreciation of buildings or parts of buildings used for research or development purposes); costs for clinical research; regular costs for the utilization of third parties’ patents for research and development purposes; other taxes related to research facilities; and fees for the filing and registration of self-generated patents that are not capitalized. Leases Payments made by the Company on operating leases, mainly in connection with the rental agreements for the premises in Austria and the United States, are charged to the consolidated statement of comprehensive income (loss) on a straight-line basis over the period of the lease. The Company has not entered into capital leases. Dividend distribution To date, Nabriva has not paid dividends. Dividend distribution to the Company’s shareholders shall be recognized as a liability in the Company’s consolidated financial statements in the period in which the dividends are approved by the Company’s shareholders. Property, plant and equipment Property, plant and equipment are stated at historical cost less accumulated depreciation and impairment. Historical costs include the acquisition price, ancillary costs and subsequent acquisition costs less any discounts received on the acquisition price. Depreciation on assets is calculated using the straight-line method over the estimated useful lives of the assets. In calculating the estimated useful life, the economic and technical life expectancy has been taken into consideration. The estimated useful lives of property, plant and equipment are as follows: 3-5 years for IT equipment, 5-10 years for laboratory equipment and 3-10 years for other plant and office equipment. The assets’ residual values and useful lives are reviewed, and adjusted if appropriate, at each reporting date. When assets are sold, closed down or scrapped, the difference between the net proceeds and the net carrying amount of the asset is recognized as a gain or a loss in other operating income or expenses. Intangible assets and other long lived assets Intangible assets, such as acquired computer software licenses, are capitalized on the basis of the costs incurred to acquire the software and bring it into use. These costs are amortized on a straight-line basis over their estimated useful lives (3-10 years). Intangible assets and long-lived assets are assessed for potential impairment when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. An impairment loss would be recognized when an asset’s fair value, determined based on undiscounted cash flows expected to be generated by the asset, is less than its carrying amount. The impairment loss would be measured as the amount by which the asset’s carrying value exceeds its fair value and recognized in these financial statements. Intangible assets are carried at cost less accumulated amortization and impairment. Short-term Investments The Company has designated investment in securities as available-for-sale securities and measures these securities at their respective fair values. Investments are classified as short-term or long-term based on the maturity date and their availability to meet current operating requirements. Investments that mature in one year or less are classified as short-term available-for-sale securities and are reported as a component of current assets. Investments that are not considered available for use in current operations are classified as long-term available-for-sale securities and are reported as a component of long-term assets. Changes in the fair value of short-term investments are recognized in other comprehensive income (loss), with the exception of interest income and foreign exchange gains/losses on monetary financial assets being recognized in the consolidated statement of comprehensive income (loss). Excluding the money market fund (see Note 13), the fair value of the Company’s short term investments is reported at their respective carrying amounts given the short-term nature of these investments. The fair value of shares in the money market fund are determined by the daily redemption price at which such shares can be sold, as quoted daily by the fund on the basis of the fund’s net asset value. For short-term investments classified as available-for-sale, a decline in fair value below acquisition cost is considered as an indicator that the securities are impaired. If any such evidence exists, the cumulative loss — measured as the difference between the acquisition cost and the current fair value considering any previous recognized impairments — is removed from other comprehensive income and recognized in the consolidated statement of comprehensive income (loss). Cash and Cash Equivalents Cash and cash equivalents are classified as cash on hand and deposits held on call with banks and may include other short-term highly liquid investments with original maturities of three months or less. They are recorded at their principal amount. Mezzanine Equity The silent partnership agreements (see Note 17), which entitled the silent partners to a proportionate share in the fair value of the Company, similar to a shareholder, including a share in profit or loss, according to an agreed participation rate, were classified as mezzanine equity pursuant to ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) , and ASC 815, Derivatives and Hedging (“ASC 815”) . The silent partnership interests were evaluated for equity or mezzanine classification based upon the nature of the partnerships settlement provisions which unilaterally provided the Company the option to settle the obligation in cash or a variable number of shares. However, when a settlement in shares cannot always be presumed, irrespective of probability of the event occurring, a classification outside of stockholders’ equity is required. Mezzanine equity was initially measured at fair value and subsequently at the redemption value at each reporting period, representing the proceeds resulting from an exit event (trade sale or initial public offering), and such amount recognized in retained earnings. Convertible Loans The Company presents convertible loans (see Note 19) as a liability in the consolidated balance sheet. The Company evaluates the requirement to bifurcate embedded options within its convertible loans in accordance with ASC 815. ASC 815 provides criteria that, if met, require companies to bifurcate conversion options from their host instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded option are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument is not remeasured at fair value under otherwise applicable generally accepted accounting principles with changes reported in fair value as they occur, and (c) a separate instrument with the same terms as the embedded option would be considered a derivative instrument. Discounts associated with convertible loans are amortized over the term of the related debt using the effective yield method. Additional Call Options The Company accounted for the additional call options issued as a result of the Convertible Loan Agreement (“CLA”) and Kreos Loan 2014 pursuant to ASC 815, which provides a two-step model to be applied in determining whether a financial instrument or an embedded feature is indexed to an issuer’s own stock. Due to the circumstances that the additional call options did not meet the “fixed for fixed” criteria under ASC 815-40, Contracts in Entity’s Own Equity (“ASC 815-40”), and did not meet the definition of a derivative, the additional call options were classified as a liability. At inception, the call options were accounted for at fair value (determined by use of the option pricing model (“OPM”)), and in subsequent periods, with changes in fair value recognized in the other income (expense), net line item within the consolidated statement of comprehensive income (loss). Prior to the extinguishment or termination of these options during 2015, the call options were valued using the option pricing method. Under this approach, each class of securities was modeled as a combination of call options with a unique claim on the assets of the company. The characteristics of each security’s class defined these claims. This reflected differences in value allocation at different company value levels that result from differences in security classes, for example from liquidation preference rights, dividend accrual, etc. The OPM used the Black-Scholes option-pricing model to price the call options. This model defines the securities’ fair values as functions of the current fair value of the Company and uses assumptions such as the anticipated timing of a potential liquidity event and the estimated volatility of the entire equity. Volatility was estimated based on the observed daily share price returns of peer companies over a historic period closely matching the period for which expected volatility is estimated. Volatility is defined as the annualized standard deviation of share price returns. In the allocation of equity, the company also considered valuation outcomes through a sale of the company compared to an initial public offering, and considered the probabilities of each at each valuation date, since the treatment of the liquidation rights were different for these two events. The aggregate value per security class was then divided by the number of securities outstanding to arrive at the value per security. The valuations relied on DCF models to derive the total enterprise value. The cash flow projections were based on probability-weighted scenarios which considered estimates of time to market, market share and pricing of lefamulin in the target indications. The cash flow projections were estimated over a period equal to the expected patent life, and a terminal value period was not applied. The expected sales were estimated using a detailed market model that comprises historical and expected number of therapies as well as prices of relevant drugs per indication and region, based on market reports, surveys and estimates by management. Production and research and development costs were estimated at the indication level with general and administrative costs and selling and marketing costs estimated at the overall company level. A WACC of 16.0% was applied for each valuation date. The OPM relies on the anticipated timing and probability of a liquidity event based on then current plans and estimates of the management as per each valuation date. As of July 4, 2014 and December 31, 2014 the probability of an initial public offering was estimated at 60% (2013 and earlier: 10%) and of a sale at 40% (2013 and earlier: 90%). As of December 31, 2014, the estimated volatility was 65% (2013: 80%) based on historical trading volatility for the publicly traded peer companies and a time to liquidity of 0.5 years for the IPO scenario and 2.5 years for the trade sales scenario (2013: 1.2 years and 4.4 years, respectively). As of June 30, 2015, the time to liquidity was estimated at 0.6 years (June 30, 2014: 1.0 years) for the initial public offering scenario and 2.3 years (June 30, 2014: 3.0 years) for the trade sale scenario, resulting in an estimated volatility as of June 30, 2015 of 55% (June 30, 2014: 65%). Beneficial Conversion Features The Company may issue financial instruments that may contain embedded conversion features. If these embedded conversion options have been assessed under ASC 815 for bifurcation and concluded separate accounting is not required, further analysis to determine if a beneficial conversion features exists is performed. A beneficial conversion feature exists on the date a financial instrument is issued when the fair value of the underlying convertible shares is in excess of the effective conversion price based on the proceeds allocated to the convertible instrument (i.e. intrinsic value). When determining the effective conversion price, the fair value of any attached equity instruments is considered, if any related equity instruments were granted with the original instrument. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in capital. The intrinsic value of any contingent beneficial conversion features is recognized upon the resolution of the contingency. Depending on the nature of the instrument, the beneficial conversion feature and contingent beneficial conversion feature are amortized to either the earliest date of conversion or the term of the instrument. Modification and Extinguishment Accounting The Company evaluates amendments to its debt in accordance with ASC 470, Debt (“ASC 470”), for modification and extinguishment accounting. The evaluation includes considering whether the present value of cash flows of the new debt instrument is at least 10 percent different from the present cash flows of the old debt instrument as well as considering the impact of the amendment to an embedded conversion option. In situations where the instruments are not substantially different, an increase in fair value of the embedded conversion option was also evaluated. Employee Benefits The Company is obliged to pay jubilee benefits in accordance with the collective bargaining agreement for the chemical industry, whereby the employee is entitled to receive a jubilee payment after being employed for a certain number of years. The Company’s net obligation in respect of these long-term employee benefits according to ASC 710-10-25 is the amount of future benefit that employees have earned in return for their service in the current and prior periods. That benefit is discounted to determine its present value. Remeasurements are recognized in profit or loss under salaries in the period in which they arise. The Company is further legally required to make monthly contributions to a state plan classified as defined contribution plan. These contributions are recognized under expenses for social security and payroll related taxes. Share-Based Payments The Company operates several share-based compensation plans. The fair value of such stock-based compensation is recognized as an expense for the employee services received in exchange for the grant of the options under the Stock Option Plan 2007 and the Stock Option Plan 2015 (see Note 15) or shares under the Founders’ Program 2007 (see Note 15). Share-based payments to employees and others providing similar services are measured at the fair value of the equity awards at the grant date and recognized as an expense over the

Research Premium and Grant Reve

Research Premium and Grant Revenue	12 Months Ended
	Dec. 31, 2016
Research Premium and Grant Revenue
Research Premium and Grant Revenue	3. Research Premium and Grant Revenue Research premium and grant revenue consists of the following items: Year ended December 31, (in thousands) 2014 2015 2016 Research premium $ $ $ Government grants — Grants from WWFF and ZIT Total $ $ $

Research and Development Expens

Research and Development Expenses	12 Months Ended
	Dec. 31, 2016
Research and Development Expenses
Research and Development Expenses	4. Research and Development Expenses Research and development expenses include the following items: Year ended December 31, (in thousands) 2014 2015 2016 Research materials and purchased services $ $ $ Staff costs Other research and development expenses Depreciation and amortization Total $ $ $ Research materials and purchased services include all expenses for materials and services in respect of research activities. For the year ended December 31, 2016 other research and development expenses consist of $1.2 million in infrastructure expenses, $1.2 million in advisory and external consultancy expenses, $0.5 million in intellectual property and trademark related expenses, $0.4 million in travel expenses and $0.1 million in other expenses. For the year ended December 31, 2015 other research and development expenses consist of $1.3 million in infrastructure expenses, $0.9 million in advisory and external consultancy expenses, $0.4 million in intellectual property and trademark related expenses, $0.4 million in travel expenses and $0.1 million in other expenses. For the year ended December 31, 2014 other research and development expenses consist of $1.4 million in infrastructure expenses, $0.7 million in advisory and external consultancy expenses, $0.7 million in intellectual property and trademark related expenses, $0.2 million in travel expenses and $0.1 million in other expenses.

General and Administrative Expe

General and Administrative Expenses	12 Months Ended
	Dec. 31, 2016
General and Administrative Expenses
General and Administrative Expenses	5. General and Administrative Expenses General and administrative expenses include the following items: Year ended December 31, (in thousands) 2014 2015 2016 Other general and administrative expenses $ $ $ Staff costs Depreciation and amortization Total $ $ $ For the year ended December 31, 2016 other general and administrative expenses include the following: $2.4 million advisory and external consultancy expenses, $1.1 million tax consulting, payroll accounting, accounting and auditing expenses, $1.4 million infrastructure expenses, $1.0 million legal expenses, $0.3 million travel expenses, $0.4 million supervisory board fees and expenses and $1.3 million other expenses. For the year ended December 31, 2015 other general and administrative expenses include the following: $1.3 million advisory and external consultancy expenses, $0.7 million tax consulting, payroll accounting, accounting and auditing expenses, $0.7 million infrastructure expenses, $0.5 million legal expenses, $0.3 million travel expenses, $0.2 million supervisory board fees and expenses and $0.7 million other expenses. For the year ended December 31, 2014 other general and administrative expenses include the following: $0.5 million advisory and external consultancy expenses, $0.5 million tax consulting, payroll accounting, accounting and auditing expenses, $0.5 million infrastructure expenses, $0.3 million legal expenses, $0.1 million travel expenses, $0.1 million supervisory board fees and expenses and $0.2 million other expenses.

Post-employment benefit obligat

Post-employment benefit obligations	12 Months Ended
	Dec. 31, 2016
Post-employment benefit obligations
Post-employment benefit obligations	6. Post-employment benefit obligations As required under Austrian labor law, the Company makes contributions to a state plan classified as defined contribution plan ( Mitarbeitervorsorgekasse ) for its employees in Austria. Monthly contributions to the plan are 1.53% of salary with respect to each employee and are recognized as expense in the period incurred. In the year ended December 31, 2016, contribution costs amounted to $59 (2015: $58, 2014: $65). For employees of Nabriva Therapeutics US, Inc., the Company makes contributions to a defined contribution plan as defined in subsection 401(k) of the Internal Revenue Code. The Company matches 100% of the first 3% of the employee’s voluntary contribution to the plan and 50% of the next 2% contributed by the employee. Contributions are recognized as expense in the period incurred. In the years ended December 31, 2016, 2015 and 2014 contribution expenses were $157, $57 and $4, respectively.

Other income (expense), net

Other income (expense), net	12 Months Ended
	Dec. 31, 2016
Other income (expense), net
Other income (expense), net	7. Other income (expense), net Year ended December 31, (in thousands) 2014 2015 2016 Foreign exchange gain $ $ $ Foreign exchange losses ) ) ) Other ) ) Total $ ) $ $ )

Income tax (expense) benefit

Income tax (expense) benefit	12 Months Ended
	Dec. 31, 2016
Income tax (expense) benefit
Income tax (expense) benefit	8. Income tax (expense) benefit Income (loss) before income taxes attributable to domestic and international operations, consists of the following: Year ended December 31 (in thousands) 2014 2015 2016 Domestic $ ) $ ) $ ) Foreign ) ) Income (loss) before income taxes $ ) $ ) $ ) Income tax (expense) benefit consists of the following: Year ended December 31 (in thousands) 2014 2015 2016 Current tax $ $ $ Domestic ) ) ) Foreign ) ) ) Deferred tax Domestic — — — Foreign ) Total income tax (expense) benefit $ ) $ $ The reconciliation between the Austrian statutory income tax rate of 25% and our effective tax rate is as follows: Year ended December 31 (% of pre-tax income) 2014 2015 2016 Austria statutory income tax rate % % % Non-deductible expenses ) ) ) Income not subject to tax Tax credits Foreign rate differential Other Valuation allowance ) ) ) Effective income tax rate )% % % The following table summarizes the components of deferred income tax balances: (in thousands) 2015 2016 Deferred tax assets: Net operating loss carryforwards $ $ Equity compensation Non-deductible reserves Total deferred tax assets $ $ Valuation allowance ) ) Net deferred tax assets Deferred tax liabilities: Financial liabilities Property, plant and equipment Total deferred tax liability $ $ Deferred tax, net $ $ The table below summarizes changes in the deferred tax valuation allowance: Year ended December 31, (in thousands) 2014 2015 2016 Balance at beginning of year $ ) $ ) $ ) Charges to costs and expenses ) ) ) Write-offs — — — Balance at end of year $ ) $ ) $ ) As of December 31, 2016 and 2015 the Company had cumulative net operating loss carryforwards of $216.9 million and $162.5 million, respectively. The net operating loss carryforwards have no expiration. Due to uncertainty regarding the ability to realize the benefit of deferred tax assets relating to certain net operating loss carryforwards, valuation allowances have been established to reduce deferred tax assets to an amount that is more likely than not to be realized. Realization of the remaining net deferred tax assets will depend on the generation of sufficient taxable income in the appropriate jurisdiction, the reversal of deferred tax liabilities, tax planning strategies and other factors prior to the expiration of the carryforwards. A change in the estimates used to make this determination could require a reduction in the deferred tax assets if they are no longer considered realizable. On the basis of this evaluation, as of December 31, 2016 and 2015, the Company has recorded a valuation allowance of $54,114 and $40,487, respectively, to recognize only the portion of the deferred tax asset that is more likely than not to be realized. The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased or if objective negative evidence in the form of cumulative losses is no longer present and additional weight is given to subjective evidence such as our projections for growth. At December 31, 2016 and 2015, the Company had no uncertain tax positions and does not expect any material increase or decrease in income tax expense related to examinations or changes in uncertain tax positions. The Company files income tax returns in Austria. In addition, the Company’s foreign subsidiary files separate income tax returns in the United States and state jurisdictions in which they are located. Tax years 2011 and forward remain open for examination for Austrian tax purposes and years 2014 and forward remain open for examination for the Company’s foreign subsidiary. The Company’s policy is to record interest and penalties related to tax matters in income tax expense.

Earnings (Loss) per Share

Earnings (Loss) per Share	12 Months Ended
	Dec. 31, 2016
Earnings (Loss) per Share
Earnings (Loss) per Share	9. Earnings (Loss) per Share Basic earnings/losses per share Basic earnings/losses per share is calculated by dividing the net earnings/loss attributable to shareholders by the weighted average number of shares outstanding during the year. Year ended December 31, (in thousands, except per share data) 2014 2015 2016 Net loss for the period $ ) $ ) $ ) Adjustment to redemption value of silent partnerships ) ) — Net loss attributable to shareholders ) ) ) Weighted average number of shares outstanding Excluded treasury shares on December 31 — Basic loss per share $ ) $ ) $ ) Diluted earnings/losses per share Diluted earnings/losses per share is calculated by adjusting the weighted average number of shares outstanding to assume conversion of all dilutive potential shares. In 2014 and 2015 diluted losses per share equal basic losses per share. The effect of 190,432 (2015: 132,706; 2014: 24,133) potentially dilutive share options has been excluded from the diluted loss per share calculation because it would result in a decrease in the loss per share for the period and is therefore not to be treated as dilutive. Year ended December 31, (in thousands, except per share data) 2014 2015 2016 Net loss for the period $ ) $ ) $ ) Adjustment to redemption value of silent parterships ) ) — Loss used to determine dilutive earnings per share $ ) $ ) $ ) Weighted average number of shares outstanding Adjustment for Assumed conversion of convertible loans n/a n/a n/a Share options n/a n/a n/a Weighted average number of shares for diluted loss per share Diluted loss per share $ ) $ ) $ )

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment
Property, Plant and Equipment	10. Property, Plant and Equipment (in thousands) 2015 2016 IT equipment $ $ Laboratory appliances Other equipment $ $ Less: Accumulated depreciation $ ) $ ) Property, plant and equipment, net $ $

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2016
Fair Value Measurement
Fair Value Measurement	11. Fair Value Measurement US GAAP establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows: · Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities. · Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (as prices) or indirectly (as exchange rates). · Level 3: Valuation techniques that include inputs for the asset or liability that are not based on observable market data (those are unobservable inputs) and significant to the overall fair value measurement. The following table presents the financial instruments measured at fair value and classified by level according to the fair value measurement hierarchy: (in thousands) Level 1 Level 2 Level 3 Total December 31, 2016 Assets: Short-term investments: Available-for-sale investments $ $ $ — $ Term Deposits — — Total Assets $ $ $ — $ Liabilities: Call Options $ — $ — $ — $ — Total Liabilities $ — $ — $ — $ — (in thousands) Level 1 Level 2 Level 3 Total December 31, 2015 Assets: Short-term investments: Available-for-sale investments $ $ $ — $ Term Deposits — — Total Assets $ $ $ — $ Liabilities: Call Options $ — $ — $ — $ — Total Liabilities $ — $ — $ — $ — As of December 31, 2016 and December 31, 2015, the Company held short term investments (see Note 13) classified as both Level 1 and Level 2, and the Company did not hold any Level 3 financial instruments measured at fair value. All such instruments, which included the call option liabilities from the Kreos and CLA loans, were exercised or terminated in 2015. Prior to this, fair values of the call options (Level 3) were determined using the option pricing model. There were no transfers between Level 1 and 2 in the years ended December 31, 2016 and December 31, 2015. There were no changes in valuation techniques during the year ended December 31, 2016. The following table shows the reconciliation of Level 3 fair value measurements of financial liabilities: (in thousands) Level 3 Financial December 31, 2015 Opening balance $ Total (gains) losses in profit or loss Settlement by issued equity instruments ) Waiver of option rights ) Fx differences ) Closing Balance $ — December 31, 2016 Opening balance $ — Closing Balance $ — Total (gains) losses for the period result from the valuation of call options are included in the Other income (expense) line item in the consolidated statement of comprehensive income (loss). The line item “Settlement by issued equity instruments” in the table above refers to the exercise of call options related to the Kreos Loan 2014 in the amount of $1,420. In addition, the “Waiver of option rights” line item relates to the waiving of call option rights by the CLA lenders, and was recorded as additional paid-in capital as the waiver was treated as a capital transaction (see Note 19).

Long-term and current receivabl

Long-term and current receivables	12 Months Ended
	Dec. 31, 2016
Long-term and current receivables
Long-term and current receivables	12. Long-term and current receivables As of December 31 (in thousands) 2015 2016 Deposits $ $ Total long-term receivables $ $ Research premium VAT and other taxes Receivables from grant revenue — Other receivables Total current receivables $ $ Total $ $ Long-term receivables relate to rent deposits made on the office building in Vienna, Austria and King of Prussia, Pennsylvania, United States. Current receivables are all due within one year. No receivables are past due or impaired. As of December 31, 2016 and December 31, 2015, no receivables were pledged.

Short-term investments

Short-term investments	12 Months Ended
	Dec. 31, 2016
Short-term investments
Short-term investments	13. Short-term investments The Company’s short-term investments were as follows: As of December 31, 2016 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Short-term investments: $ — $ — $ — $ — Available-for-sale investments $ $ — $ ) $ Term deposits $ $ — $ — $ Total $ $ — $ ) $ As of December 31, 2015 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Short-term investments: $ — $ — $ — $ — Available-for-sale investments $ $ — $ ) $ Term deposits $ $ — $ — $ Total $ $ — $ ) $ As of December 31, 2016 and December 31, 2015 the Company’s short-term investments were classified as available-for-sale and comprised a (i) money market fund that invests all of its assets, excluding cash and deposits, in short term USD-denominated debt securities, and (ii) a U.S. treasury note.

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Dec. 31, 2016
Cash and Cash Equivalents
Cash and Cash Equivalents	14. Cash and Cash Equivalents Cash and cash equivalents were as follows: As of December 31 (in thousands) 2015 2016 Cash on hand $ — $ — Cash at bank Total cash and cash equivalents $ $

Share-Based Payments

Share-Based Payments	12 Months Ended
	Dec. 31, 2016
Share-Based Payments
Share-Based Payments	15. Share-Based Payments Stock Option Plan 2007 On September 12, 2007 the Company’s management and supervisory boards resolved to implement a stock option plan (“SOP”) for all employees (including members of the management board) with open-ended contracts of employment with the Company and for selected members of the supervisory board of the Company and further participants. The stock option plan became effective on September 28, 2007 and the shareholders of the Company resolved to amend the SOP on September 17, 2009, May 7, 2010 and June 30, 2015. The total number of options eligible that can be granted and vested in the beneficiaries under the SOP does not exceed 29,889 (the overall number of options). The options grant the beneficiaries the right to acquire shares in the Company. The vesting period for the options is four years following the grant date. On the last day of the last calendar month of the first year of the vesting period, 25% of the options attributable to each beneficiary are automatically vested. On the last day of the last calendar month of the second year of the vesting period, a further 25% of the options are vested. During the third and fourth years of the vesting period, the remaining 50% of the options vest on a monthly pro rata basis (i.e. 2.083% per month). Notwithstanding any of the above, the exercise of vested options was only permissible in case of a liquidation event (e.g. sale of 50% or more of the shares or assets of the Company, merger of the Company) or a qualified public offering. Since the closing of the initial public offering of the Company on September 23, 2015 the beneficiaries are entitled to exercise their vested options until the end of the exercise period on September 27, 2017. The beneficiaries are not entitled to transfer vested options except to individuals by way of inheritance or bequest. Options do not entitle beneficiaries to exercise any shareholder rights. Beneficiaries may exercise shareholder rights only in virtue of any shares they hold. As of December 31, 2016, the vested option rights outstanding under the SOP 2007 amount to $2,016 (2015: $4,200, 2014: $4,253) and are recorded under additional paid in capital. Movements in the number of share options outstanding and their related weighted average exercise prices concerning the Stock Option Plan 2007 are as follows: 2014 2015 2016 Stock Option Plan 2007 Weighted Options Weighted Options Weighted Options Aggregate Outstanding as of January 1 Granted — — — — Exercised — — ) ) Forfeited — — — ) Outstanding as of December 31 $ Vested and exercisable as of December 31 — — $ The total intrinsic value of options exercised during the year ended December 31, 2016 was $2,246 (2015: $119, 2014 — not applicable). The 1,088 options granted on August 31, 2014 were valued based on the option pricing method as of July 4, 2014. There were no significant results from our development programs, or any other changes that may affect the company value, between July 4, 2014 and August 31, 2014. Therefore the Company believed the July 2014 valuation was still reasonable. The significant inputs to the option pricing method are as follows: Input parameters Granted on Expected volatility % Expected term of options 1.3 years Risk-free interest rate % Dividend yield — The weighted average remaining contractual life of all options granted under the SOP 2007 is 0.4 years. The weighted average fair value of the options granted in 2014 was $209.11 per share. Stock-based compensation expense under the Stock Option Plan 2007 was $95, $78, and $96 for the years ended December 31, 2016, 2015 and 2014, respectively. We did not accrue any income tax benefit under the Stock Option Plan 2007 for the years ended December 31, 2016, December 31, 2015 and December 31, 2014. The weighted average share price at the date of exercise of options exercised during the year ended December 31, 2016 was $77.70 (2015: $86.60; 2014 — not applicable). Stock Option Plan 2015 On April 2, 2015, the Company’s shareholders, management board and supervisory board adopted the Stock Option Plan 2015 and the shareholders approved an amended and restated version of the Stock Option Plan 2015 on June 30, 2015. An amendment to the amended and restated Stock Option Plan 2015 was approved by the shareholders on July 22, 2015. The Stock Option Plan 2015 became effective on July 3, 2015 upon the registration with the commercial register in Austria of the conditional capital increase approved by the shareholders on June 30, 2015. The Stock Option Plan 2015 initially provided for the grant of options for up to 95,000 common shares to the Company’s employees, including members of the management board, and to members of the supervisory board. Following the closing of the initial public offering of the Company, the overall number of options increased to 177,499 shares. Following approval by the Company’s shareholders at its 2016 annual general meeting, the number of shares available for issuance under the Stock Option Plan 2015 was increased to 346,235 common shares. Each vested option grants the beneficiary the right to acquire one share in the Company. The vesting period for the options is four years following the grant date. On the last day of the last calendar month of the first year of the vesting period, 25% of the options attributable to each beneficiary are automatically vested. During the second, third and fourth years of the vesting period, the remaining 75% of the options vest on a monthly pro rata basis (i.e. 2.083% per month). Since the closing of the initial public offering of the Company on September 23, 2015 the beneficiaries are entitled to exercise their vested options until the 10 th anniversary of the date of their participation. The beneficiaries are not entitled to transfer vested options except to individuals by way of inheritance or bequest. Options do not entitle beneficiaries to exercise any shareholder rights. Beneficiaries may only exercise shareholder rights if and to the extent he holds shares. As at December 31, 2016, the vested option rights outstanding under the SOP 2015 amounted to $3,543 (2015: $1,274, 2014: $0) and is recorded under additional paid in capital. Movements in the number of share options outstanding and their related weighted average exercise prices concerning the Stock Option Plan 2015 are as follows: 2015 2016 Stock Option Plan 2015 Weighted Options Weighted Options Aggregate Outstanding as of January 1 — — Granted Exercised — — ) Forfeited ) ) Outstanding as of December 31 $ Vested and exercisable as of December 31 $ The total intrinsic value of options exercised during the year ended December 31, 2016 was $181 (2015 — not applicable). Options outstanding at the end of the year under the SOP 2015 have the following expiry dates and exercise prices: Option Series/Grant date Expiry date Exercise Options Options (1) Granted on July 6, 2015 July 6, 2025 (2) Granted on September 30, 2015 September 30, 2025 (3) Granted on October 31, 2015 October 31, 2025 (4) Granted on November 30, 2015 November 30, 2025 (5) Granted on December 31, 2015 December 31, 2025 (6) Granted on January 31, 2016 January 31, 2026 — (7) Granted on February 5, 2016 February 5, 2026 — (8) Granted on March 31, 2016 March 31, 2026 — (9) Granted on April 30, 2016 April 30, 2026 — (10) Granted on May 31, 2016 May 31, 2026 — (11) Granted on June 30, 2016 June 30, 2026 — (12) Granted on July 31, 2016 July 31, 2026 — (13) Granted on August 26,2016 August 26,2026 — (14) Granted on August 31, 2016 August 31, 2026 — (15) Granted on September 30, 2016 September 30, 2026 — (16) Granted on October 31, 2016 October 31, 2026 — (17) Granted on November 30, 2016 November 30, 2026 — Total — Stock-based compensation expense under the Stock Option Plan 2015 was $2,450 for the year ended December 31, 2016 (2015: $1,274). The total income tax benefit under the Stock Option Plan 2015 recognized in the statement of operations and comprehensive income (loss) for the year ended December 31, 2016 was $643 (2015: $382; 2014: not applicable). The weighted average fair value of the options granted during the period was $30.58 per share (2015: $70.72, 2014: not applicable). The 109,355 options granted in 2015 were valued based on a Black Scholes option pricing model. The significant inputs into the model were as follows: Input parameters Series 1 Series 2 Series 3 Series 4 Series 5 Grant date share price in $ Exercise price in $ Expected volatility % % % % % Expected term of options 2.0 years 2.2 years 2.2 years 2.2 years 2.3 years Risk-free interest rate -0.210 % -0.231 % -0.307 % -0.400 % -0.323 % Dividend yield — — — — — The expected price volatility is based on historical trading volatility for the publicly traded peer companies under consideration of the remaining life of the options. The weighted average remaining contractual life of the options granted in the year ended December 31, 2016 is 9.2 years (2015: 9.6 years). As of December 31, 2016, there was $5,701 of total unrecognized compensation expense, related to unvested options granted under the plan, which will be recognized over the weighted —average remaining period of 2.2 years. Founders’ Program 2007 The Founders’ Program 2007 is a further share-based payment scheme the beneficiaries of which are Dr. Gerd Ascher and Dr. Rodger Novak. There remain 623 shares available in form of stock options at an exercise price of €1.00 per share and otherwise on the same terms and conditions as set out in the Company’s Stock Option Plan 2007. The 623 options vested as follows: 25% of the options (156 shares) vested in November 2007. A further 25% (155 shares) vested in February 2008. The remaining 50% vested during the period from March 2008 to February 2010 on a monthly pro rata basis (i.e., 2.083% per month, or 13 shares). The fair value of each of these options at grant date is $144.23 per share. The options are fully vested but not yet exercised. Therefore, a balance of $122 (2015: $122, 2014: $122) is recorded in additional paid in capital as at December 31, 2016. The corresponding expense was recorded over the vesting period under other employee benefit expenses. No further options were granted under the Founders’ Program 2007, and no options were forfeited or exercised in 2014, 2015 and 2016.

April 2015 Financing

April 2015 Financing	12 Months Ended
	Dec. 31, 2016
April 2015 Financing
Financing
Financing	16. April 2015 Financing On March 31, 2015, the Company entered into an agreement with certain existing and new investors to issue and sell common shares with contractual preference rights, including a preferred dividend right (the “April 2015 financing”). The contractual preference rights arose under a shareholders agreement, signed on April 2, 2015, by all shareholders of the Company (the “Shareholders Agreement 2015”) entered into in connection with the April 2015 financing. In connection with this financing, the Company agreed to sell the shares in two tranches. In April 2015, Nabriva closed the sale of the first tranche of 730,162 shares, including the sale of 511,188 shares at a price per share of $87.71 for $44,836 in cash consideration and the sale of 218,974 shares in exchange for the conversion of outstanding convertible loans and silent partnerships investments. The Company also agreed to sell a second tranche of shares to these investors at the investors’ option for an aggregate purchase price of $70,000 if the Company had not completed a public offering in the United States within specified parameters or by a specified date. In connection with this April 2015 financing, all existing convertible loan agreements and silent partnership interests were converted to common shares with contractual preference rights under the Shareholders Agreement 2015. On March 31, 2015, the Company, its existing investors and new investors in the April 2015 financing signed the Investment and Subscription Agreement 2015, or ISA 2015. The signing of the ISA 2015 resulted in the following effects with respect to the Company’s existing financial instruments: a) the lenders under all existing convertible loan agreements, or CLAs, irrevocably waived their claims for payment of interest accrued on the loan amounts, b) all CLA lenders irrevocably waived and acknowledged the termination of their call option rights granted under the CLAs, and c) all silent partners irrevocably agreed to the forfeiture of their claims for payment of interest accrued on their silent partnership investments. Pursuant to the Company’s shareholders agreement, signed on April 2, 2015, the holders of the shares issued in its April 2015 financing were granted certain preferential rights. These rights include the right of certain shareholders to acquire additional common shares against payment of the nominal amount of €1.00 per share following an appropriate resolution of all of its shareholders, which the Company refers to as the preferred dividend. The preferred dividend accrued at a rate per annum of 8%, based on the number of days that have elapsed from the issuance of such shares until the occurrence of certain triggering events, including an initial public offering, a sale of the company, voluntary conversion to preference shares by the shareholders, and a liquidation. The preferred dividend was cumulative and perpetual, and could be paid in cash or shares based on a shareholders vote. Upon the closing of the Company’s initial public offering and the issuance of the shares for nominal value in satisfaction of the preferred dividends, all contractual preference rights terminated in December 2015. The shares from the April 2015 financing were recorded upon registration of the capital increase in the Austrian commercial register in May 2015. As a result of the preferred dividend rights, which are not legally separable, the Company’s deemed to have issued common shares accompanied by preferred dividends that may be settled for cash or shares. Accordingly, the proceeds from the April 2015 financing, including the consideration from conversion of the convertible loan agreements and silent partnership interests, were recorded as mezzanine equity. A mezzanine equity classification arises as a result of the dividend provision in the Shareholders Agreement 2015, which the Company’s shareholders have covenanted to vote in favor of the requisite shareholder resolutions to allow it to satisfy the preferred dividend rights. As a result, (i) the Company’s could not avoid fulfilling the preferred dividend rights if a triggering event occurred that was outside its control, and (ii) could not always presume a settlement in shares. Therefore, when a settlement in shares cannot always be presumed for an event not solely within the control of the issuer, irrespective of probability of the event occurring, a classification outside of stockholders’ equity is required. Mezzanine equity was initially measured at fair value and subsequently at the redemption value at each reporting period, representing the proceeds resulting from an exit event (trade sale or initial public offering), and such amount recognized in retained earnings. The April 2015 financing and the related conversion of the Company’s outstanding convertible loan agreements and silent partnership interests resulted in total consideration of $77.3 million which was recorded in mezzanine equity. Upon the closing of the Company’s initial public offering in September 2015, a triggering event occurred as described above, and the holders of the preferred dividend right received 17,149 additional shares against payment of the nominal amount of €1.00 per share, effectively removing the mezzanine equity classification.

December 2016 Financing

December 2016 Financing	12 Months Ended
	Dec. 31, 2016
December 2016 Financing
Financing
Financing	17. December 2016 Financing On December 19, 2016, the Company completed a rights offering and a related underwritten offering for the sale of an aggregate of 588,127 common shares resulting in aggregate gross proceeds of approximately $24.8 million and net proceeds to the Company of approximately $20.6 million, after deducting underwriting fees and offering expenses. In the rights offering, holders of American Depositary Shares, or ADSs, received 0.276 ADS rights for each ADS owned of record on November 29, 2016. One ADS right entitled an ADS holder to subscribe for and purchase one new ADS at the subscription price of $4.32 per ADS, the U.S. dollar equivalent of €4.014 per ADS. An aggregate of 1,592,750 ADSs, representing 159,275 common shares, were subscribed for by holders of ADSs. Each ADS represents one tenth of a common share. In the rights offering, holders of common shares received the common share right to subscribe for and purchase 0.276 new common shares, at a subscription price of €40.14 per new common share for each common share owned of record on November 29, 2016. An aggregate of 102,077 new common shares were subscribed for by holders of common shares. Pursuant to an underwriting agreement that the Company entered into with Cantor Fitzgerald & Co., dated December 14, 2016, Cantor Fitzgerald & Co. agreed to purchase 326,775 common shares, representing all of the unsubscribed common shares in the rights offering, at a purchase price of €40.14 per common share for purposes of resale of ADSs representing such unsubscribed common shares.

Investment from Silent Partners

Investment from Silent Partnership	12 Months Ended
	Dec. 31, 2016
Investment from Silent Partnership
Investment from Silent Partnership	18. Investment from Silent Partnership In 2014 and 2015, the Company issued silent partnership interests which entitled the silent partners to a proportionate share in the fair value of the Company, similar to a shareholder, including a share in profit or loss, according to an agreed participation rate. The silent partnership interests represented a residual interest in the Company. An ordinary termination by the Company or the silent partner was possible after June 30, 2018 and January 31, 2019. Apart from the ordinary termination, the parties to the contracts were also entitled to terminate the contracts early for material cause without observing a notice period (collectively the “termination options”). Upon exercise of the termination options, Nabriva had the unilateral option to settle the obligation in cash or a variable number of its own equity instruments. Although share settlement of such obligation was within complete control of Nabriva, scenarios existed where a settlement in shares was not economically beneficial to Nabriva and as a result share settlement could not always be presumed. Therefore, the silent partnership interests had been classified as mezzanine equity according to ASC 480. According to ASC 480, contributions of the silent partners were initially measured at fair value with adjustment for the effect of a beneficial conversion feature. At initial recognition, the intrinsic value of the beneficial conversion feature was allocated from the proceeds of the silent partnerships to additional paid-in capital, thereby, reducing the associated balance of the silent partnership interests. Subsequently, the silent partnership interests were measured at the redemption value at each reporting period, representing the silent partners’ share in the proceeds resulting from an exit event (trade sale or initial public offering), which has been calculated by use of the option pricing model. The beneficial conversion feature was amortized from the date of issuance to the earliest conversion date of the silent partnership interests. The Company entered into agreements with existing and new investors to issue and sell common shares with contractual preference rights under the Shareholders Agreement 2015 (“April 2015 financing”) during the year ended December 31, 2015. In connection with this April 2015 financing all silent partnership interests were converted to common shares with contractual preference rights. At the time of conversion, a contingent beneficial conversion feature was also recognized immediately prior to conversion due to an update to the conversion price in conjunction with the April 2015 financing, which was an unresolved contingent event at the time of issuance of the silent partnership interests. The contingent beneficial conversion feature was allocated to additional paid in capital, and fully amortized upon conversion. Upon closing of the April 2015 financing all silent partnerships interests were terminated and the respective claims converted into equity. The resulting effect on redemption value, which was calculated using the option pricing model, is shown under “Adjustment to fair value” in the table below. The amounts outstanding for the silent partnership interests are as follows: (in thousands) 2015 2016 Carrying amount as of January 1 $ $ — Issuance (net of $150 transaction costs) — Recognition of beneficial conversion features ) Adjustment to redemption value(1) — Settlement by issued equity instruments ) — Fx differences ) — Closing Balance as of December 31 $ — $ — (1) Amount includes amortization of beneficial conversion features

Kreos Loan 2014

Kreos Loan 2014	12 Months Ended
	Dec. 31, 2016
Kreos Loan 2014
Kreos Loan 2014
Kreos Loan 2014	19. Kreos Loan 2014 On July 4, 2014 Nabriva entered into a loan agreement with Kreos Capital IV (“Kreos”) to obtain a loan in the amount of $6,643 (“Kreos Loan 2014”), payable monthly. The loan ranked senior to the convertible loans. In connection with the loan agreement, Nabriva granted Kreos options to purchase shares of the Company (“Kreos Options”). Pursuant to the option agreement dated July 4, 2014 the number of shares to be issued was calculated by dividing $996 (i.e. 15% of the loan granted by Kreos by the price per share of the latest external financing as of the date of exercise. As collateral for the loan, the Company pledged its intellectual property, fixed assets exceeding a book value of €1,000, the receivables related to the research premium and its bank accounts. The Company was allowed to sell or otherwise disburse of any of pledged fixed asset in the ordinary course of business, and also to withdraw any amounts from the pledged bank accounts, as long as it was not in default of the provisions of the loan agreement. Nabriva was entitled to prepay the loan at $3,462, which included a premium, in accordance with the terms of the loan agreement, which it did in November 2015. (in thousands) Carrying amount as of January 1 $ Effective interest accrued Interest paid ) Monthly installments ) Early repayment ) Loss on early extinguishment of debt Fx differences ) Carrying amount as of December 31, 2015 $ — Carrying amount as of December 31, 2016 $ — On May 13, 2015, Kreos exercised their call option rights for 9,107 common shares with contractual preference rights identical to the preference rights of the new shares issued in the April 2015 financing. The conversion price upon exercise was $87.71 per share as agreed in the April 2015 financing. The fair value of the call options was determined using the OPM and amounted to $1,420 before reclassification to equity upon exercise (See Note 11).

Convertible Loans

Convertible Loans	12 Months Ended
	Dec. 31, 2016
Convertible Loan Agreements
Convertible Loans
Convertible Loans	20. Convertible Loans Between July 2011 and January 2015 Nabriva entered into five convertible loan agreements (collectively the “CLAs”), with certain of its shareholders. The lenders had the right to convert their entire claim for repayment of the loans into common shares with contractual preference rights in Nabriva. Certain of the CLAs were issued with detachable call options (“Additional Call Options”). The key terms of the CLAs and the Additional Call Options are outlined below as at December 31, 2015: Convertible Loan Additional Call Options Tranche Year Amount Interest Rate Conversion Maturity Date Number Exercise Price Maturity CLA1 2011 $ % $ Dec. 31, 2015 $ Dec. 31, 2015 CLA2(4) 2012 $ — $ Dec. 31, 2015 $ Dec. 31, 2015 CLA3 2013 $ % $ Dec. 31, 2015 — CLA4 2014 $ % $ Dec. 31, 2015 — CLA5 2015 $ % $ Dec. 31, 2015 — (1) Conversion price is $247.54 or the share price agreed in an external equity financing agreement (where the financing round is at least $5 million). (2) The shares to be delivered should either have the same rights as the latest common shares with contractual preference rights issued or the common shares with contractual preference rights issued in the course of the new equity financing. (3) Cumulative accrued interest is expected to be paid at maturity of the CLA. (4) In the event of exercise of the early repayment the lenders would receive a repayment premium equal to one time the principal amount, i.e. double the principal amount. The conversion options embedded in the CLAs did not meet the definition of a derivative in accordance with ASC 815. Therefore, the conversion option was not bifurcated from the CLAs. The proceeds from the CLAs were first ascribed to the fair value of the Additional Call Options (if applicable) with the remaining balance allocated to the liability recognized for the CLAs. In addition, certain of the CLAs have been adjusted by the effects of a beneficial conversion feature. For those instruments, the intrinsic value of the beneficial conversion feature at initial recognition was allocated from the proceeds of the CLAs to additional paid-in capital, thereby, reducing the value of the recognized liability. According to ASC 470, the beneficial conversion feature was amortized from the date of issuance to the stated redemption date. The discount associated with Additional Call Options and the beneficial conversion features were amortized using the effective yield method and recognized in Interest expense in the consolidated statement of comprehensive income. The Additional Call Options are detachable freestanding financial instruments and were recognized separately from the CLAs. The Additional Call Options did not meet the definition of a derivative requirements under ASC 815 and “fixed for fixed” criteria under ASC 815-40. Accordingly, the Additional Call Options were classified as a liability. At inception of the agreements, the Additional Call Options were accounted for at fair value (determined by use of the option pricing model), and in subsequent periods with changes in fair value were recognized in the Other income (expense), net line item within the consolidated statement of comprehensive income (loss). For detail on the outstanding balance, change in fair value and the settlement of the Additional Call Option please see the Level 3 Rollforward table in Note 11. In conjunction with the issuance of the fifth CLA on January 8, 2015, the repayment dates of all outstanding CLAs were extended to December 31, 2015. In accordance with ASC 470, the extension was considered a modification. As a result, the Company recognized a $738 discount as a reduction to the CLA balance and an associated increase in additional paid-in capital to reflect the increase in the value of the conversion options related to the extension. In connection with the April 2015 financing all existing CLAs were converted to common shares with contractual preference rights under the Shareholders Agreement 2015 at a conversion price of $87.71 In connection with this April 2015 financing an Investment and Subscription Agreement was signed on March 31, 2015 where all existing CLA lenders irrevocably waived their claims for payment of interest accrued on the CLA amounts and agreed to the termination of the Additional Call Options issued in connection with certain CLAs. A contingent beneficial conversion feature was also recognized for all CLAs immediately prior to conversion as the conversion price had been updated in conjunction with the April 2015 financing, which was an unresolved contingent event at the time of issuance of the CLAs. The contingent beneficial conversion feature was allocated to additional paid in capital and fully amortized and recognized in Interest expense upon conversion. The outstanding amounts for the CLAs were adjusted for the interest waived and the balances were reclassified into equity upon issuance of the new shares based upon the exercise of the conversion option. The amounts recognized as a result of the modification to the maturity date of the CLAs and amounts waived by the lenders have been accounted for a capital transaction and recorded in additional paid-in capital as these were transactions with shareholders of the Company and therefore considered related parties (See Note 22). Movements in CLAs are analyzed as follows: As of December 31 (in thousands) 2015 2016 Carrying amount at January 1 (including interest payable) $ $ — Proceeds of issue — Extension of CLA repayment date — Modification ) Recognition of beneficial conversion features(1) ) — Interest expense recognized(2) — Waiving of interest(3) ) — Settlement by issued equity instruments ) — Fx differences ) — Carrying amount at December 31 $ — $ — (1) Includes both initial recognition of the beneficial conversion feature in relation to CLA and the recognition of the contingent beneficial conversion feature upon conversion of the CLAs into equity of the Company in Interest expense. (2) Includes both effective interest and the accretion of the discount related to beneficial conversion features recognized. (3) The waiver of interest (as described above) was recorded in additional paid-in capital with a corresponding decrease in the CLA balance outstanding.

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	12 Months Ended
	Dec. 31, 2016
Accrued Expenses and Other Liabilities
Accrued Expenses and Other Liabilities	21. Accrued Expenses and Other Liabilities Other non-current liabilities include an obligation to pay jubilee benefits arising under the collective bargaining agreement for the chemical industry, by which employees are entitled to receive jubilee payments after being employed for a certain number of years. For this obligation a provision of $107 (2015: $84) has been made. The Company’s net obligation in respect of the jubilee payments is calculated annually by an independent actuary in accordance with ASC 710-10-25 using the projected unit credit method. The principle actuarial assumptions used were as follows: discount rate of 1.3% (2015: 2.0%) and retirement at the age of 61.5-65 for men and 56.5-65 for women, future annual salary increases of 3%. Accrued expenses and other current liabilities include the following: As of December 31 (in thousands) 2015 2016 Research and development related costs $ $ Payroll and related costs Accounting, tax and audit services Other Total other current liabilities $ $

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies
Commitments and Contingencies	22. Commitments and Contingencies Commitments Lease Agreements In March 2007, a lease agreement for an unlimited period starting in December 2007 was entered into with CONTRA Liegenschaftsverwaltung GMBH for the use of business and research premises at Leberstrasse 20, 1110 Vienna. Within the first 10 years the contract can only be terminated under certain conditions. The monthly rental fee for the premises and laboratory furniture is $85 (2015: $84; 2014: $101) and includes all operating costs. Additional monthly costs for facility management and security services amount to $9 (2015: $9; 2014: $11). In December 2014, a lease agreement for a two-year period starting December 2014 was entered into with EOS AT 1000 CONTINENTAL, LLC, for the use of office premises at 1000 Continental Drive, Suite 450, King of Prussia, PA 19406, USA. The monthly rental fee is $9 (2015: $9). In July 2015, a lease agreement was entered into with CardConnect, LLC, for the use of office premises at 1000 Continental Drive, Suite 600, King of Prussia, PA 19406, USA with the lease term continuing until December 2023. The monthly base rental fee is $40 (2015: $39) with a yearly rent adjustment per square foot starting as of August 2016. Rent expense was $1,263, $861 and $858 for the years ended December 31, 2016, 2015 and 2014, respectively. The obligations under the lease agreements are payable as follows: As of December 31, (in thousands) 2015 2016 No later than 1 year $ $ Later than 1 year and no later than 5 years Later than 5 years Total $ $ Other contractual commitments In addition to the agreements above, the Company has entered into a number of other agreements also entailing financial commitments for the future and relating mainly to services provided by third parties in connection with the conduct of clinical trials and other research and development activities. Some of these commitments are also subject to early termination clauses exercisable at the option of the Company. The remaining payments to be made under these agreements, if all milestones and other conditions are met, are estimated to be as follows: As of December 31, (in thousands) 2015 2016 No later than 1 year $ $ Later than 1 year and no later than 5 years Later than 5 years — — Total $ $ Contingencies The Company has no contingent liabilities in respect of legal claims arising in the ordinary course of business.

Related Parties

Related Parties	12 Months Ended
	Dec. 31, 2016
Related Parties
Related Parties	23. Related Parties Convertible loan agreements The Company entered into CLAs see (Note 19) with some of its shareholders with an aggregate principle amount of $18,172 before conversion into common shares with contractual preference rights in the course of the April 2015 financing. The following shareholders and other related parties entered into the five CLAs entered into prior to conversion. CLA1 CLA2 CLA3 CLA4 CLA 5 July 27, March 16, November July 4, January 8, Phase4 Ventures III LP (“Phase4”)      The Wellcome Trust Limited (“Wellcome Trust”)     Wellcome Trust Investments 3 Unlimited  HBM Healthcare (Cayman) Ltd. (before HBM BioVentures (Cayman) Ltd.) (“HBM Healthcare”)      HBM BioCapital Invest Ltd. (“HBM BioCapital”)      The Global Life Science Ventures Fund II Limited Partnership (“GLSV Fund”)    The Global Life Science Ventures Fonds II GmbH & Co KG (“GLSV Fonds”)    Novartis Bioventures, Ltd. (NBV)   Novartis International Pharmaceutical Investment Ltd. (NIPI)  George Talbot   Colin Broom  As of July 11, 2014 Wellcome Trust Investments 3 Unlimited transferred it rights and obligations under the CLA2 to The Wellcome Trust Limited. Relationship with George Talbot We paid Talbot Advisors LLC, a single-member limited liability company of which George H. Talbot is the principal, approximately $4,500, $17,400 and $163,900 during the years ended December 31, 2016, 2015, and 2014, for Dr. Talbot’s service as chairman of our Clinical Advisory Board and for consulting services related to our clinical development strategy, engagement with strategic partners and related travel expenses.

Selected Quarterly Financial In

Selected Quarterly Financial Information (Unaudited)	12 Months Ended
	Dec. 31, 2016
Selected Quarterly Financial Information (Unaudited)
Selected Quarterly Financial Information (Unaudited)	24. Selected Quarterly Financial Information (Unaudited) The table summarizes the unaudited consolidated financial results of operations for the quarters ended: (amounts in thousands, except per share data) March 31 June 30 September 30 December 31 2016 Quarter Ended Revenues $ $ $ $ Operating expenses ) ) ) ) Loss from operations ) ) ) ) Other income (expense) ) ) Income tax (expense) benefit ) Net loss ) ) ) ) Basic loss per share(1) $ ) $ ) $ ) $ ) Diluted loss per share(1) $ ) $ ) $ ) $ ) 2015 Quarter Ended Revenues $ $ $ $ Operating expenses ) ) ) ) Loss from operations ) ) ) ) Other income (expense) ) ) ) Income tax (expense) benefit ) ) Net loss ) ) ) ) Basic loss per share(1) $ ) $ ) $ ) $ ) Diluted loss per share(1) $ ) $ ) $ ) $ ) (1) Net income per share amounts may not agree to the per share amounts for the full year due to the use of weighted average shares for each period.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events
Subsequent Events	25. Subsequent Events The Company evaluated all events or transactions that occurred subsequent to December 31, 2016 through the date the consolidated financial statements were issued, and have not identified any such events.

Summary of Significant Accoun32

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Summary of Significant Accounting Policies
Basis of Preparation	Basis of Preparation The consolidated financial statements of Nabriva Therapeutics AG have been prepared on a historical cost basis with the exception of certain items such as available-for-sale financial assets or some financial liabilities (debt derivatives resulting from conversion rights and options) which are shown at fair value. The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and US Securities and Exchange Commission (“SEC”) regulations for annual reporting. The preparation of financial statements in conformity with US GAAP requires the use of certain critical accounting estimates. It requires management to exercise its judgment in the process of applying the Company’s accounting policies.
Recent Accounting Pronouncements	Recent Accounting Pronouncements At the time of authorization of these consolidated financial statements for publication, a number of revisions, amendments and interpretations had already been published by the FASB. None of these are expected to have a significant effect on the consolidated financial statements of the Company, except the following set out below: · In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers , an updated standard on revenue recognition. ASU 2014-09 provides enhancements to the quality and consistency of how revenue is reported by companies while also improving comparability in the financial statements of companies reporting using International Financial Reporting Standards or GAAP. The main purpose of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which a company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively and improve guidance for multiple-element arrangements. In July 2015, the FASB voted to approve a one-year deferral of the effective date of ASU 2014-09, which will be effective for the Company in the first quarter of fiscal year 2018 and may be applied on a full retrospective or modified retrospective approach. ASU 2014-09 will have no impact on the Company until it begins to generate revenue. · In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern . ASU 2014-16 explicitly requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management will assess if there is substantial doubt about an entity’s ability to continue as a going concern within one year after the issuance date. Management will consider relevant conditions that are known, and reasonably knowable, at the issuance date. Substantial doubt exists if it is probable that the entity will be unable to meet its obligations within one year after the issuance date. Disclosures will be required if conditions give rise to substantial doubt. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Early adoption is permitted. The Company has performed its assessment and determined that it has sufficient financial reasourses to meet its cash requirements into the second quarter of 2018. · In November 2015, the FASB issued ASU 2015-17, Income Taxes: Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the balance sheet classification of deferred taxes and requires that all deferred taxes be presented as noncurrent. ASU 2015-17 is effective for fiscal years beginning after December 15, 2016 with early adoption permitted. The adoption of this update is not expected to have a material effect on the Company’s financial statements. · In January 2016, FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities . ASU 2016-01 requires equity investments to be measured at fair value with changes in fair value recognized in net income; simplifies the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment; eliminates the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet; requires public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes; requires an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments; requires separate presentation of financial assets and financial liabilities by measurement category and form of financial assets on the balance sheet or the accompanying notes to the financial statements and clarifies that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets. ASU 2016-01 is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the impact that ASU 2016-01 will have on its financial statements and related disclosures. · In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods, with early adoption permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact that the standard will have on its financial statements and related disclosures. · In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting , which provides for simplification of certain aspects of employee share-based payment accounting including income taxes, classification of awards as either equity or liabilities, accounting for forfeitures and classification on the statement of cash flows. ASU 2016-09 will be effective for the Company in the first quarter of 2017 and will be applied either prospectively, retrospectively or using a modified retrospective transition approach depending on the area covered in this update. The Company is currently evaluating the impact that the standard will have on its financial statements and related disclosures. · In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) (“ASU 2016-08”), in April 2016 issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing (“ASU 2016-10”), and in May 2016, issued ASU 2016-11, Revenue Recognition (Topic 605) and Derivatives and Hedging (Topic 815): Rescission of SEC Guidance Because of Accounting Standards Updates 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 EITF Meeting (“ASU 2016-11”) . ASU 2016-08 clarifies principal versus agent considerations relating to when another party, along with the entity, is involved in providing a good or service to a customer. ASU 2016-08 requires an entity to determine whether the nature of its promise is to provide a good or service to a customer, or to arrange for the good or service to be provided to the customer by the other party. This determination is based upon whether the entity controls the good or service before it is transferred to the customer. When the entity that satisfies a performance obligation is the principal, the entity recognizes the gross amount of consideration as revenue. When the entity that satisfies the performance obligation is the agent, it recognizes the amount of any fee or commission as revenue. ASU 2016-10 clarifies the guidance in Topic 606 for identifying performance obligations in a contract as well as the implementation guidance pertaining to revenue recognition related to licensing arrangements. ASU 2016-11 rescinds several SEC Staff Announcements that are codified in Topic 605, including, among other items, guidance relating to accounting for consideration given by a vendor to a customer, as well as accounting for shipping and handling fees and freight services. The Company is currently evaluating the impacts of this standard on its financial statements and anticipates no significant effects when the standard is adoped as of the effective date. · In May 2016, the FASB also issued ASU 2016-12, Revenue from Contracts with Customers - Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”), which provides clarification on certain topics within ASU 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), including assessing collectability, presentation of sales taxes, the measurement date for non-cash consideration and completed contracts at transition, as well as providing a practical expedient for contract modifications at transition. The effective date and transition requirements for the amendments in ASU 2016-08, ASU 2016-10 and ASU 2016-12 are the same as the effective date and transition requirements of ASU 2014-09, which is effective for fiscal years, and for interim periods within those years, beginning after December 15, 2017. The Company is currently evaluating the impacts of this standard on its financial statements and anticipates no significant effects when the standard is adoped as of the effective date. · In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments . The amendments in this ASU introduce clarifications to the presentation of certain cash receipts and cash payments in the statement of cash flows. The primary updates include additions and clarifications of the classification of cash flows related to certain debt repayment activities, contingent consideration payments related to business combinations, proceeds from insurance policies, distributions from equity method investees and cash flows related to securitized receivables. This update is effective for annual periods beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption of this ASU is permitted, including in interim periods. The ASU requires retrospective application to all prior periods presented upon adoption. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its cash flows and/or disclosures, however, the Company does not anticipate that the new guidance will have a significant impact on its financial statements and related disclosures. · In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash . ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The amendments in this ASU are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company does not expect the adoption of the amendments to have a material effect on its financial statements and related disclosures.
Consolidation	Consolidation The consolidated financial statements include the financial information of Nabriva Therapeutics AG and its 100% owned subsidiary, Nabriva Therapeutics US, Inc. a Delaware corporation, founded in August 2014. All intercompany balances and transactions are eliminated.
Subsequent Events	Subsequent Events Material subsequent events are evaluated and disclosed through the report issuance date.
Segment Reporting	Segment Reporting The Company comprises a single operating and reportable segment engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The management team is the chief operating decision maker, and it reviews the consolidated operating results regularly to make decisions about the allocation of the Company’s resources, and to assess overall performance.
Foreign Currency Translation	Foreign Currency Translation Functional and presentation currency Effective January 1, 2016, the Company’s functional and reporting currency changed to the U.S. dollar (“USD”). Prior to January 1, 2016, the consolidated financial statements were presented in euro (“€”), which was the Company’s functional and presentation currency. With the expansion of Nabriva’s operations to the United States, the Company’s assets, liabilities, revenues and expenses are expected to be predominantly denominated in USD, and accordingly, the use of USD to measure and report the Company’s financial performance and financial position was considered to be more appropriate. The impact of the currency translation up to January 1, 2016 is recorded in accumulated other comprehensive income (loss). Upon the change in functional currency on January 1, 2016, all assets and liabilities of the Company’s operations were translated from their euro functional currency into USD using the exchange rates in effect on the balance sheet date, equity was translated at the historical rates and revenues, expenses, and cash flows were translated at the average rates during the reporting period presented. The resulting translation adjustments are reported under comprehensive income (loss) as a separate component of equity. Transactions and balances In preparing the financial statements of each individual group entity, transactions in currencies other than the entity’s functional currency (foreign currencies) are recognized at the exchange rates prevailing at the dates of the transactions. Foreign currency exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the consolidated statement of comprehensive income (loss).
Research Premium and Grant Revenue	Research Premium and Grant Revenue Grant revenue comprises (a) the research premium from the Austrian government, (b) grants received from the Vienna Center for Innovation and Technology ( Zentrum für Innovation, or ZIT ) and the Vienna Business Promotion Fund ( Wiener Wirtschaftsförderungsfonds, or WWFF ) and (c) the benefit of government loans at below-market interest rates. Please refer to Note 3 for further details on all forms of grant revenue. The research premium was calculated as 10% of a specified research and development cost base for the years ended December 31, 2015 and December 31, 2014. For the year ended December 31, 2016, the research premium is calculated as 12% of a specified research and development cost base. It is recognized to the extent the research and development expenses have been incurred. The WWFF grant is paid out through the landlord in the form of a monthly reduction in lease payments and is recognized over the period from grant date in March 2010 until end of the lease termination waiver term in December 2017. The ZIT grants are provided to support specific research projects and are recognized according to the progress of the respective project. All grants are non-refundable as long as the conditions of the grant are met. Nabriva is and has been in full compliance with the conditions of the grants and all related regulations. The benefit of a government loan at a below-market rate of interest is treated as a government grant. The benefit due to the difference between the market rate of interest and the rate of interest charged by the governmental organization is measured as the difference between the initial carrying value of the loan determined and the proceeds received. This benefit is deferred, and recognized through profit and loss over the term of the corresponding liabilities.
Research and Development Expenses	Research and Development Expenses All research and development costs are expensed as incurred. The following costs, in particular by their nature, constitute research and development expenses: direct personnel and material costs, related overheads for internal or external technology, engineering and other departments that provide services; costs for experimental and pilot facilities (including depreciation of buildings or parts of buildings used for research or development purposes); costs for clinical research; regular costs for the utilization of third parties’ patents for research and development purposes; other taxes related to research facilities; and fees for the filing and registration of self-generated patents that are not capitalized.
Leases	Leases Payments made by the Company on operating leases, mainly in connection with the rental agreements for the premises in Austria and the United States, are charged to the consolidated statement of comprehensive income (loss) on a straight-line basis over the period of the lease. The Company has not entered into capital leases.
Dividend distribution	Dividend distribution To date, Nabriva has not paid dividends. Dividend distribution to the Company’s shareholders shall be recognized as a liability in the Company’s consolidated financial statements in the period in which the dividends are approved by the Company’s shareholders.
Property, plant and equipment	Property, plant and equipment Property, plant and equipment are stated at historical cost less accumulated depreciation and impairment. Historical costs include the acquisition price, ancillary costs and subsequent acquisition costs less any discounts received on the acquisition price. Depreciation on assets is calculated using the straight-line method over the estimated useful lives of the assets. In calculating the estimated useful life, the economic and technical life expectancy has been taken into consideration. The estimated useful lives of property, plant and equipment are as follows: 3-5 years for IT equipment, 5-10 years for laboratory equipment and 3-10 years for other plant and office equipment. The assets’ residual values and useful lives are reviewed, and adjusted if appropriate, at each reporting date. When assets are sold, closed down or scrapped, the difference between the net proceeds and the net carrying amount of the asset is recognized as a gain or a loss in other operating income or expenses.
Intangible assets and other long lived assets	Intangible assets and other long lived assets Intangible assets, such as acquired computer software licenses, are capitalized on the basis of the costs incurred to acquire the software and bring it into use. These costs are amortized on a straight-line basis over their estimated useful lives (3-10 years). Intangible assets and long-lived assets are assessed for potential impairment when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. An impairment loss would be recognized when an asset’s fair value, determined based on undiscounted cash flows expected to be generated by the asset, is less than its carrying amount. The impairment loss would be measured as the amount by which the asset’s carrying value exceeds its fair value and recognized in these financial statements. Intangible assets are carried at cost less accumulated amortization and impairment.
Short-term Investments	Short-term Investments The Company has designated investment in securities as available-for-sale securities and measures these securities at their respective fair values. Investments are classified as short-term or long-term based on the maturity date and their availability to meet current operating requirements. Investments that mature in one year or less are classified as short-term available-for-sale securities and are reported as a component of current assets. Investments that are not considered available for use in current operations are classified as long-term available-for-sale securities and are reported as a component of long-term assets. Changes in the fair value of short-term investments are recognized in other comprehensive income (loss), with the exception of interest income and foreign exchange gains/losses on monetary financial assets being recognized in the consolidated statement of comprehensive income (loss). Excluding the money market fund (see Note 13), the fair value of the Company’s short term investments is reported at their respective carrying amounts given the short-term nature of these investments. The fair value of shares in the money market fund are determined by the daily redemption price at which such shares can be sold, as quoted daily by the fund on the basis of the fund’s net asset value. For short-term investments classified as available-for-sale, a decline in fair value below acquisition cost is considered as an indicator that the securities are impaired. If any such evidence exists, the cumulative loss — measured as the difference between the acquisition cost and the current fair value considering any previous recognized impairments — is removed from other comprehensive income and recognized in the consolidated statement of comprehensive income (loss).
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents are classified as cash on hand and deposits held on call with banks and may include other short-term highly liquid investments with original maturities of three months or less. They are recorded at their principal amount.
Mezzanine Equity	Mezzanine Equity The silent partnership agreements (see Note 17), which entitled the silent partners to a proportionate share in the fair value of the Company, similar to a shareholder, including a share in profit or loss, according to an agreed participation rate, were classified as mezzanine equity pursuant to ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) , and ASC 815, Derivatives and Hedging (“ASC 815”) . The silent partnership interests were evaluated for equity or mezzanine classification based upon the nature of the partnerships settlement provisions which unilaterally provided the Company the option to settle the obligation in cash or a variable number of shares. However, when a settlement in shares cannot always be presumed, irrespective of probability of the event occurring, a classification outside of stockholders’ equity is required. Mezzanine equity was initially measured at fair value and subsequently at the redemption value at each reporting period, representing the proceeds resulting from an exit event (trade sale or initial public offering), and such amount recognized in retained earnings.
Convertible Loans	Convertible Loans The Company presents convertible loans (see Note 19) as a liability in the consolidated balance sheet. The Company evaluates the requirement to bifurcate embedded options within its convertible loans in accordance with ASC 815. ASC 815 provides criteria that, if met, require companies to bifurcate conversion options from their host instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded option are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument is not remeasured at fair value under otherwise applicable generally accepted accounting principles with changes reported in fair value as they occur, and (c) a separate instrument with the same terms as the embedded option would be considered a derivative instrument. Discounts associated with convertible loans are amortized over the term of the related debt using the effective yield method.
Additional Call Options	Additional Call Options The Company accounted for the additional call options issued as a result of the Convertible Loan Agreement (“CLA”) and Kreos Loan 2014 pursuant to ASC 815, which provides a two-step model to be applied in determining whether a financial instrument or an embedded feature is indexed to an issuer’s own stock. Due to the circumstances that the additional call options did not meet the “fixed for fixed” criteria under ASC 815-40, Contracts in Entity’s Own Equity (“ASC 815-40”), and did not meet the definition of a derivative, the additional call options were classified as a liability. At inception, the call options were accounted for at fair value (determined by use of the option pricing model (“OPM”)), and in subsequent periods, with changes in fair value recognized in the other income (expense), net line item within the consolidated statement of comprehensive income (loss). Prior to the extinguishment or termination of these options during 2015, the call options were valued using the option pricing method. Under this approach, each class of securities was modeled as a combination of call options with a unique claim on the assets of the company. The characteristics of each security’s class defined these claims. This reflected differences in value allocation at different company value levels that result from differences in security classes, for example from liquidation preference rights, dividend accrual, etc. The OPM used the Black-Scholes option-pricing model to price the call options. This model defines the securities’ fair values as functions of the current fair value of the Company and uses assumptions such as the anticipated timing of a potential liquidity event and the estimated volatility of the entire equity. Volatility was estimated based on the observed daily share price returns of peer companies over a historic period closely matching the period for which expected volatility is estimated. Volatility is defined as the annualized standard deviation of share price returns. In the allocation of equity, the company also considered valuation outcomes through a sale of the company compared to an initial public offering, and considered the probabilities of each at each valuation date, since the treatment of the liquidation rights were different for these two events. The aggregate value per security class was then divided by the number of securities outstanding to arrive at the value per security. The valuations relied on DCF models to derive the total enterprise value. The cash flow projections were based on probability-weighted scenarios which considered estimates of time to market, market share and pricing of lefamulin in the target indications. The cash flow projections were estimated over a period equal to the expected patent life, and a terminal value period was not applied. The expected sales were estimated using a detailed market model that comprises historical and expected number of therapies as well as prices of relevant drugs per indication and region, based on market reports, surveys and estimates by management. Production and research and development costs were estimated at the indication level with general and administrative costs and selling and marketing costs estimated at the overall company level. A WACC of 16.0% was applied for each valuation date. The OPM relies on the anticipated timing and probability of a liquidity event based on then current plans and estimates of the management as per each valuation date. As of July 4, 2014 and December 31, 2014 the probability of an initial public offering was estimated at 60% (2013 and earlier: 10%) and of a sale at 40% (2013 and earlier: 90%). As of December 31, 2014, the estimated volatility was 65% (2013: 80%) based on historical trading volatility for the publicly traded peer companies and a time to liquidity of 0.5 years for the IPO scenario and 2.5 years for the trade sales scenario (2013: 1.2 years and 4.4 years, respectively). As of June 30, 2015, the time to liquidity was estimated at 0.6 years (June 30, 2014: 1.0 years) for the initial public offering scenario and 2.3 years (June 30, 2014: 3.0 years) for the trade sale scenario, resulting in an estimated volatility as of June 30, 2015 of 55% (June 30, 2014: 65%).
Beneficial Conversion Features	Beneficial Conversion Features The Company may issue financial instruments that may contain embedded conversion features. If these embedded conversion options have been assessed under ASC 815 for bifurcation and concluded separate accounting is not required, further analysis to determine if a beneficial conversion features exists is performed. A beneficial conversion feature exists on the date a financial instrument is issued when the fair value of the underlying convertible shares is in excess of the effective conversion price based on the proceeds allocated to the convertible instrument (i.e. intrinsic value). When determining the effective conversion price, the fair value of any attached equity instruments is considered, if any related equity instruments were granted with the original instrument. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in capital. The intrinsic value of any contingent beneficial conversion features is recognized upon the resolution of the contingency. Depending on the nature of the instrument, the beneficial conversion feature and contingent beneficial conversion feature are amortized to either the earliest date of conversion or the term of the instrument.
Modification and Extinguishment Accounting	Modification and Extinguishment Accounting The Company evaluates amendments to its debt in accordance with ASC 470, Debt (“ASC 470”), for modification and extinguishment accounting. The evaluation includes considering whether the present value of cash flows of the new debt instrument is at least 10 percent different from the present cash flows of the old debt instrument as well as considering the impact of the amendment to an embedded conversion option. In situations where the instruments are not substantially different, an increase in fair value of the embedded conversion option was also evaluated.
Employee Benefits	Employee Benefits The Company is obliged to pay jubilee benefits in accordance with the collective bargaining agreement for the chemical industry, whereby the employee is entitled to receive a jubilee payment after being employed for a certain number of years. The Company’s net obligation in respect of these long-term employee benefits according to ASC 710-10-25 is the amount of future benefit that employees have earned in return for their service in the current and prior periods. That benefit is discounted to determine its present value. Remeasurements are recognized in profit or loss under salaries in the period in which they arise. The Company is further legally required to make monthly contributions to a state plan classified as defined contribution plan. These contributions are recognized under expenses for social security and payroll related taxes.
Share-Based Payments	Share-Based Payments The Company operates several share-based compensation plans. The fair value of such stock-based compensation is recognized as an expense for the employee services received in exchange for the grant of the options under the Stock Option Plan 2007 and the Stock Option Plan 2015 (see Note 15) or shares under the Founders’ Program 2007 (see Note 15). Share-based payments to employees and others providing similar services are measured at the fair value of the equity awards at the grant date and recognized as an expense over the respective vesting period. Since the closing of the IPO, beneficiaries under the Stock Option Plan 2007 and Stock Option Plan 2015 can exercise their vested options. In the year ended December 31, 2016, 14,790 options have been exercised. Social security contributions associated with share-based payment awards are accounted for as a liability, which is recognized on the date of the event triggering the measurement and payment of the tax to the taxing authority; or the date the options are exercised. Further, the Company issued substance participation rights to the members of the management board, which represent a liability award under ASC 718, Compensation — Stock Compensation (see Note 15) whereby the Company is obligated to make cash payments based on a certain formula upon the occurrence of certain liquidation events only. The achievement of such liquidation events are not considered probable and so no historical amounts have been recognized as stock-based compensation expense. As of December 31, 2014, all substance participation rights were terminated, hence the fair value was zero. The nominal amounts of the participation rights were required to be repaid in cash even in case of an extraordinary termination, and therefore they had been recognized separately as a liability in the consolidated balance sheet.
Income Tax	Income Tax The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. In recognizing the benefit of tax positions, the Company has taken or expects to take, the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.

Research Premium and Grant Inco

Research Premium and Grant Income (Tables)	12 Months Ended
	Dec. 31, 2016
Research Premium and Grant Revenue
Schedule of research premium and grant income	Year ended December 31, (in thousands) 2014 2015 2016 Research premium $ $ $ Government grants — Grants from WWFF and ZIT Total $ $ $

Research and Development Expe34

Research and Development Expenses (Tables)	12 Months Ended
	Dec. 31, 2016
Research and Development Expenses
Schedule of research and development expenses	Year ended December 31, (in thousands) 2014 2015 2016 Research materials and purchased services $ $ $ Staff costs Other research and development expenses Depreciation and amortization Total $ $ $

General and Administrative Ex35

General and Administrative Expenses (Tables)	12 Months Ended
	Dec. 31, 2016
General and Administrative Expenses
Schedule of General and administrative expenses	Year ended December 31, (in thousands) 2014 2015 2016 Other general and administrative expenses $ $ $ Staff costs Depreciation and amortization Total $ $ $

Other income (expense), net (Ta

Other income (expense), net (Tables)	12 Months Ended
	Dec. 31, 2016
Other income (expense), net
Schedule of other income (expense), net	Year ended December 31, (in thousands) 2014 2015 2016 Foreign exchange gain $ $ $ Foreign exchange losses ) ) ) Other ) ) Total $ ) $ $ )

Income tax (expense) benefit (T

Income tax (expense) benefit (Tables)	12 Months Ended
	Dec. 31, 2016
Income tax (expense) benefit
Schedule of income (loss) before income taxes attributable to domestic and international operations	Year ended December 31 (in thousands) 2014 2015 2016 Domestic $ ) $ ) $ ) Foreign ) ) Income (loss) before income taxes $ ) $ ) $ )
Schedule of income tax (expense) benefit	Year ended December 31 (in thousands) 2014 2015 2016 Current tax $ $ $ Domestic ) ) ) Foreign ) ) ) Deferred tax Domestic — — — Foreign ) Total income tax (expense) benefit $ ) $ $
Schedule of effective income tax rate reconciliation	Year ended December 31 (% of pre-tax income) 2014 2015 2016 Austria statutory income tax rate % % % Non-deductible expenses ) ) ) Income not subject to tax Tax credits Foreign rate differential Other Valuation allowance ) ) ) Effective income tax rate )% % %
Summary of the components of deferred income tax balances	(in thousands) 2015 2016 Deferred tax assets: Net operating loss carryforwards $ $ Equity compensation Non-deductible reserves Total deferred tax assets $ $ Valuation allowance ) ) Net deferred tax assets Deferred tax liabilities: Financial liabilities Property, plant and equipment Total deferred tax liability $ $ Deferred tax, net $ $
Summary of changes in the deferred tax valuation allowance	Year ended December 31, (in thousands) 2014 2015 2016 Balance at beginning of year $ ) $ ) $ ) Charges to costs and expenses ) ) ) Write-offs — — — Balance at end of year $ ) $ ) $ )

Earnings (Loss) per Share (Tabl

Earnings (Loss) per Share (Tables)	12 Months Ended
	Dec. 31, 2016
Earnings (Loss) per Share
Schedule of basic earnings/losses per share	Year ended December 31, (in thousands, except per share data) 2014 2015 2016 Net loss for the period $ ) $ ) $ ) Adjustment to redemption value of silent partnerships ) ) — Net loss attributable to shareholders ) ) ) Weighted average number of shares outstanding Excluded treasury shares on December 31 — Basic loss per share $ ) $ ) $ )
Schedule of diluted earnings/losses per share	Year ended December 31, (in thousands, except per share data) 2014 2015 2016 Net loss for the period $ ) $ ) $ ) Adjustment to redemption value of silent parterships ) ) — Loss used to determine dilutive earnings per share $ ) $ ) $ ) Weighted average number of shares outstanding Adjustment for Assumed conversion of convertible loans n/a n/a n/a Share options n/a n/a n/a Weighted average number of shares for diluted loss per share Diluted loss per share $ ) $ ) $ )

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment
Schedule of property, plant and equipment	(in thousands) 2015 2016 IT equipment $ $ Laboratory appliances Other equipment $ $ Less: Accumulated depreciation $ ) $ ) Property, plant and equipment, net $ $

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2016
Fair Value Measurement
Schedule of the financial instruments measured at fair value and classified by level according to the fair value measurement hierarchy	(in thousands) Level 1 Level 2 Level 3 Total December 31, 2016 Assets: Short-term investments: Available-for-sale investments $ $ $ — $ Term Deposits — — Total Assets $ $ $ — $ Liabilities: Call Options $ — $ — $ — $ — Total Liabilities $ — $ — $ — $ — (in thousands) Level 1 Level 2 Level 3 Total December 31, 2015 Assets: Short-term investments: Available-for-sale investments $ $ $ — $ Term Deposits — — Total Assets $ $ $ — $ Liabilities: Call Options $ — $ — $ — $ — Total Liabilities $ — $ — $ — $ —
Schedule of the reconciliation of Level 3 fair value measurements of financial liabilities	(in thousands) Level 3 Financial December 31, 2015 Opening balance $ Total (gains) losses in profit or loss Settlement by issued equity instruments ) Waiver of option rights ) Fx differences ) Closing Balance $ — December 31, 2016 Opening balance $ — Closing Balance $ —

Long-term and current receiva41

Long-term and current receivables (Tables)	12 Months Ended
	Dec. 31, 2016
Long-term and current receivables
Schedule of long-term and current receivables	As of December 31 (in thousands) 2015 2016 Deposits $ $ Total long-term receivables $ $ Research premium VAT and other taxes Receivables from grant revenue — Other receivables Total current receivables $ $ Total $ $

Short-term investments (Tables)

Short-term investments (Tables)	12 Months Ended
	Dec. 31, 2016
Short-term investments
Schedule of short-term investments	As of December 31, 2016 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Short-term investments: $ — $ — $ — $ — Available-for-sale investments $ $ — $ ) $ Term deposits $ $ — $ — $ Total $ $ — $ ) $ As of December 31, 2015 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Short-term investments: $ — $ — $ — $ — Available-for-sale investments $ $ — $ ) $ Term deposits $ $ — $ — $ Total $ $ — $ ) $

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Dec. 31, 2016
Cash and Cash Equivalents
Schedule of cash and cash equivalents	As of December 31 (in thousands) 2015 2016 Cash on hand $ — $ — Cash at bank Total cash and cash equivalents $ $

Share-Based Payments (Tables)

Share-Based Payments (Tables)	12 Months Ended
	Dec. 31, 2016
Stock Option Plan 2007
Share-Based Payments
Schedule of movements of share options outstanding and their related weighted average exercise prices	2014 2015 2016 Stock Option Plan 2007 Weighted Options Weighted Options Weighted Options Aggregate Outstanding as of January 1 Granted — — — — Exercised — — ) ) Forfeited — — — ) Outstanding as of December 31 $ Vested and exercisable as of December 31 — — $
Schedule of inputs to the option pricing method	Input parameters Granted on Expected volatility % Expected term of options 1.3 years Risk-free interest rate % Dividend yield —
Stock Option Plan 2015
Share-Based Payments
Schedule of movements of share options outstanding and their related weighted average exercise prices	2015 2016 Stock Option Plan 2015 Weighted Options Weighted Options Aggregate Outstanding as of January 1 — — Granted Exercised — — ) Forfeited ) ) Outstanding as of December 31 $ Vested and exercisable as of December 31 $
Schedule of options outstanding	Option Series/Grant date Expiry date Exercise Options Options (1) Granted on July 6, 2015 July 6, 2025 (2) Granted on September 30, 2015 September 30, 2025 (3) Granted on October 31, 2015 October 31, 2025 (4) Granted on November 30, 2015 November 30, 2025 (5) Granted on December 31, 2015 December 31, 2025 (6) Granted on January 31, 2016 January 31, 2026 — (7) Granted on February 5, 2016 February 5, 2026 — (8) Granted on March 31, 2016 March 31, 2026 — (9) Granted on April 30, 2016 April 30, 2026 — (10) Granted on May 31, 2016 May 31, 2026 — (11) Granted on June 30, 2016 June 30, 2026 — (12) Granted on July 31, 2016 July 31, 2026 — (13) Granted on August 26,2016 August 26,2026 — (14) Granted on August 31, 2016 August 31, 2026 — (15) Granted on September 30, 2016 September 30, 2026 — (16) Granted on October 31, 2016 October 31, 2026 — (17) Granted on November 30, 2016 November 30, 2026 — Total —
Schedule of inputs to the option pricing method	Input parameters Series 1 Series 2 Series 3 Series 4 Series 5 Grant date share price in $ Exercise price in $ Expected volatility % % % % % Expected term of options 2.0 years 2.2 years 2.2 years 2.2 years 2.3 years Risk-free interest rate -0.210 % -0.231 % -0.307 % -0.400 % -0.323 % Dividend yield — — — — —

Investment from Silent Partne45

Investment from Silent Partnership (Tables)	12 Months Ended
	Dec. 31, 2016
Investment from Silent Partnership
Schedule of amounts outstanding for the silent partnership	(in thousands) 2015 2016 Carrying amount as of January 1 $ $ — Issuance (net of $150 transaction costs) — Recognition of beneficial conversion features ) Adjustment to redemption value(1) — Settlement by issued equity instruments ) — Fx differences ) — Closing Balance as of December 31 $ — $ — (1) Amount includes amortization of beneficial conversion features

Kreos Loan 2014 (Tables)

Kreos Loan 2014 (Tables)	12 Months Ended
	Dec. 31, 2016
Kreos Loan 2014
Kreos Loan 2014
Schedule of movement in debt carrying amount	(in thousands) Carrying amount as of January 1 $ Effective interest accrued Interest paid ) Monthly installments ) Early repayment ) Loss on early extinguishment of debt Fx differences ) Carrying amount as of December 31, 2015 $ — Carrying amount as of December 31, 2016 $ —

Convertible Loans (Tables)

Convertible Loans (Tables)	12 Months Ended
	Dec. 31, 2016
Convertible Loans
Schedule of key terms of the CLAs and Additional Call Options	Convertible Loan Additional Call Options Tranche Year Amount Interest Rate Conversion Maturity Date Number Exercise Price Maturity CLA1 2011 $ % $ Dec. 31, 2015 $ Dec. 31, 2015 CLA2(4) 2012 $ — $ Dec. 31, 2015 $ Dec. 31, 2015 CLA3 2013 $ % $ Dec. 31, 2015 — CLA4 2014 $ % $ Dec. 31, 2015 — CLA5 2015 $ % $ Dec. 31, 2015 — (1) Conversion price is $247.54 or the share price agreed in an external equity financing agreement (where the financing round is at least $5 million). (2) The shares to be delivered should either have the same rights as the latest common shares with contractual preference rights issued or the common shares with contractual preference rights issued in the course of the new equity financing. (3) Cumulative accrued interest is expected to be paid at maturity of the CLA. (4) In the event of exercise of the early repayment the lenders would receive a repayment premium equal to one time the principal amount, i.e. double the principal amount.
Convertible Loan Agreements
Convertible Loans
Schedule of movement in debt carrying amount	As of December 31 (in thousands) 2015 2016 Carrying amount at January 1 (including interest payable) $ $ — Proceeds of issue — Extension of CLA repayment date — Modification ) Recognition of beneficial conversion features(1) ) — Interest expense recognized(2) — Waiving of interest(3) ) — Settlement by issued equity instruments ) — Fx differences ) — Carrying amount at December 31 $ — $ — (1) Includes both initial recognition of the beneficial conversion feature in relation to CLA and the recognition of the contingent beneficial conversion feature upon conversion of the CLAs into equity of the Company in Interest expense. (2) Includes both effective interest and the accretion of the discount related to beneficial conversion features recognized. (3) The waiver of interest (as described above) was recorded in additional paid-in capital with a corresponding decrease in the CLA balance outstanding.

Accrued Expenses and Other Li48

Accrued Expenses and Other Liabilities (Tables)	12 Months Ended
	Dec. 31, 2016
Accrued Expenses and Other Liabilities
Schedule of accrued expenses and other current liabilities	As of December 31 (in thousands) 2015 2016 Research and development related costs $ $ Payroll and related costs Accounting, tax and audit services Other Total other current liabilities $ $

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies
Schedule of obligations payable under the lease agreements	As of December 31, (in thousands) 2015 2016 No later than 1 year $ $ Later than 1 year and no later than 5 years Later than 5 years Total $ $
Schedule of remaining payments to be made under other contractual agreements	As of December 31, (in thousands) 2015 2016 No later than 1 year $ $ Later than 1 year and no later than 5 years Later than 5 years — — Total $ $

Related Parties (Tables)

Related Parties (Tables)	12 Months Ended
	Dec. 31, 2016
Related Parties
Schedule of CLAs by shareholders and other related parties	CLA1 CLA2 CLA3 CLA4 CLA 5 July 27, March 16, November July 4, January 8, Phase4 Ventures III LP (“Phase4”)      The Wellcome Trust Limited (“Wellcome Trust”)     Wellcome Trust Investments 3 Unlimited  HBM Healthcare (Cayman) Ltd. (before HBM BioVentures (Cayman) Ltd.) (“HBM Healthcare”)      HBM BioCapital Invest Ltd. (“HBM BioCapital”)      The Global Life Science Ventures Fund II Limited Partnership (“GLSV Fund”)    The Global Life Science Ventures Fonds II GmbH & Co KG (“GLSV Fonds”)    Novartis Bioventures, Ltd. (NBV)   Novartis International Pharmaceutical Investment Ltd. (NIPI)  George Talbot   Colin Broom 

Selected Quarterly Financial 51

Selected Quarterly Financial Information (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2016
Selected Quarterly Financial Information (Unaudited)
Schedule of unaudited consolidated financial results of operations	(amounts in thousands, except per share data) March 31 June 30 September 30 December 31 2016 Quarter Ended Revenues $ $ $ $ Operating expenses ) ) ) ) Loss from operations ) ) ) ) Other income (expense) ) ) Income tax (expense) benefit ) Net loss ) ) ) ) Basic loss per share(1) $ ) $ ) $ ) $ ) Diluted loss per share(1) $ ) $ ) $ ) $ ) 2015 Quarter Ended Revenues $ $ $ $ Operating expenses ) ) ) ) Loss from operations ) ) ) ) Other income (expense) ) ) ) Income tax (expense) benefit ) ) Net loss ) ) ) ) Basic loss per share(1) $ ) $ ) $ ) $ ) Diluted loss per share(1) $ ) $ ) $ ) $ ) (1) Net income per share amounts may not agree to the per share amounts for the full year due to the use of weighted average shares for each period.

Organization and Business Act52

Organization and Business Activities - General (Details)	Dec. 31, 2016
Nabriva Therapeutics US, Inc.
Percentage ownership by reporting entity	100.00%

Organization and Business Act53

Organization and Business Activities - Liquidity (Details) $ in Millions	Dec. 31, 2016USD ($)
Cash and cash equivalents and short term investments
Cash and cash equivalents and short term investments	$ 83.9

Organization and Business Act54

Organization and Business Activities - December 2016 Financing (Details) - USD ($) $ in Thousands	Dec. 19, 2016	Dec. 31, 2016
Financing
Gross proceeds from sale of shares		$ 24,822
December 2016 Financing | Common Stock
Financing
Number of shares sold	588,127
Gross proceeds from sale of shares	$ 24,800
Net proceeds from sale of shares, after deducting underwriting fees and offering expenses	$ 20,600

Organization and Business Act55

Organization and Business Activities - IPO (Details) $ / shares in Units, $ in Thousands	Sep. 30, 2015€ / sharesshares	Sep. 30, 2015USD ($)shares	Sep. 23, 2015$ / sharesshares	Dec. 31, 2015USD ($)	Sep. 30, 2015$ / shares
IPO
Shares issued price per share | € / shares	€ 1
Number of common shares represented by each ADS share			0.1
Gross proceeds from initial public offering | $				$ 106,088
IPO, including Over-Allotment Option
IPO
For aggregate number of ADS shares issued, the aggregate number of common shares represented		1,035,000
IPO, including Over-Allotment Option | ADS
IPO
Number of shares sold		10,350,000
Gross proceeds from initial public offering | $		$ 106,100
Net proceeds from sale of shares, after deducting underwriting fees and offering expenses | $		$ 92,400
IPO
IPO
For aggregate number of ADS shares issued, the aggregate number of common shares represented			900,000
IPO | ADS
IPO
Number of shares sold			9,000,000
Shares issued price per share | $ / shares			$ 10.25
Over-Allotment Option
IPO
For aggregate number of ADS shares issued, the aggregate number of common shares represented	135,000
Over-Allotment Option | ADS
IPO
Number of shares sold	1,350,000
Shares issued price per share | $ / shares					$ 10.25

Organization and Business Act56

Organization and Business Activities - April 2015 Financing (Details) € / shares in Units, $ / shares in Units, $ in Thousands, € in Millions	1 Months Ended		12 Months Ended
	Apr. 30, 2015EUR (€)€ / sharesshares	Apr. 30, 2015USD ($)shares	Dec. 31, 2015USD ($)	Sep. 30, 2015€ / shares	Apr. 30, 2015USD ($)$ / shares
Financing
Shares issued price per share | € / shares				€ 1
Proceeds from April 2015 financing	€ 42.1		$ 44,836
April 2015 Financing
Financing
Number of shares sold	730,162	730,162
Number of shares issued for cash consideration	511,188	511,188
Shares issued price per share | $ / shares					$ 87.71
Proceeds from April 2015 financing | $		$ 44,836
Shares issued in exchange for the conversion of convertible loans and silent partnerships investments	218,974	218,974
Aggregate purchase price of shares to be sold in the second tranche | $					$ 70,000
April 2015 Financing | Common Stock
Financing
Shares issued price per share | € / shares	€ 82.35

Organization and Business Act57

Organization and Business Activities - Convertible Loan Agreements (Details) - Convertible Loan Agreements $ in Thousands	Mar. 31, 2015USD ($)agreement
Convertible Loans
Number of CLAs | agreement	5
Aggregate principal amount | $	$ 18,172

Organization and Business Act58

Organization and Business Activities - Silent Partnership (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Jun. 30, 2014	Dec. 31, 2015	Dec. 31, 2014
Investment from Silent Partnership
Proceeds from silent partnership	$ 900	$ 500	$ 943	$ 536

Organization and Business Act59

Organization and Business Activities - Kreos Loan (Details) - Kreos Loan 2014 € in Thousands, $ in Thousands	Jul. 04, 2014EUR (€)	Jun. 30, 2014USD ($)	Jul. 04, 2014USD ($)	Jun. 30, 2014EUR (€)
Kreos Loan 2014
Loan amount			$ 6,643	€ 5,000
Net proceeds from loan agreements | $		$ 6,200
Minimum book value of fixed assets pledged as collateral for loan | €	€ 1,000

Summary of Significant Accoun60

Summary of Significant Accounting Policies - Consolidation (Details)	Dec. 31, 2016
Nabriva Therapeutics US, Inc.
Consolidation
Percentage ownership by reporting entity	100.00%

Summary of Significant Accoun61

Summary of Significant Accounting Policies - Revenues (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Austrian Government Research Premium
Research Premium and Grant Income
Cost Base For Research Premium Grant Income Calculation	12.00%	10.00%	10.00%

Summary of Significant Accoun62

Summary of Significant Accounting Policies - Property, plant and equipment (Details)	12 Months Ended
	Dec. 31, 2016
IT equipment | Minimum
Property, Plant and Equipment
Estimated useful life of property, plant and equipment	3 years
IT equipment | Maximum
Property, Plant and Equipment
Estimated useful life of property, plant and equipment	5 years
Laboratory appliances | Minimum
Property, Plant and Equipment
Estimated useful life of property, plant and equipment	5 years
Laboratory appliances | Maximum
Property, Plant and Equipment
Estimated useful life of property, plant and equipment	10 years
Other equipment | Minimum
Property, Plant and Equipment
Estimated useful life of property, plant and equipment	3 years
Other equipment | Maximum
Property, Plant and Equipment
Estimated useful life of property, plant and equipment	10 years

Summary of Significant Accoun63

Summary of Significant Accounting Policies - Intangible assets and other long-lived assets (Details)	12 Months Ended
	Dec. 31, 2016
Minimum
Intangible assets
Estimated useful life of intangible assets	3 years
Maximum
Intangible assets
Estimated useful life of intangible assets	10 years

Summary of Significant Accoun64

Summary of Significant Accounting Policies - Additional Call Options (Details) - Other Financial Liabilities	Jun. 30, 2015	Dec. 31, 2014	Jul. 04, 2014	Jun. 30, 2014	Dec. 31, 2016	Dec. 31, 2013
Weighted Average Cost Of Capital
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Discount rate					16.00%
Black Scholes Option Pricing Method
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Probability of IPO		60.00%	60.00%			10.00%
Probability of Trade Sale		40.00%	40.00%			90.00%
Estimated Volatility	55.00%	65.00%		65.00%		80.00%
Time to Liquidity - IPO scenario	7 months 6 days	6 months		1 year		1 year 2 months 12 days
Time to Liquidity - Trade Sales scenario	2 years 3 months 18 days	2 years 6 months		3 years		4 years 4 months 24 days

Summary of Significant Accoun65

Summary of Significant Accounting Policies - Share-Based Payments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2014
Management Board
Share-Based Payments
Substance Participation Rights, Fair Value		$ 0
Stock Option Plan 2007 And Stock Option Plan 2015
Share-Based Payments
Exercise of options (in shares)	14,790

Research Premium and Grant Re66

Research Premium and Grant Revenue (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Research Premium and Grant Revenue
Research premium									$ 6,232	$ 3,594	$ 1,366
Government grants										67	560
Grants from WWFF and ZIT									250	106	472
Total	$ 2,307	$ 971	$ 1,785	$ 1,419	$ 974	$ 1,297	$ 899	$ 597	$ 6,482	$ 3,767	$ 2,398

Research and Development Expe67

Research and Development Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Research and development expenses disclosures
Depreciation and amortisation	$ 233	$ 153	$ 166
Total	47,994	23,604	9,355
Research and development expenses
Research and development expenses disclosures
Research materials and purchased services	36,565	14,957	1,760
Staff costs	7,863	5,447	4,349
Other research and development expenses	3,432	3,099	3,123
Depreciation and amortisation	134	101	123
Total	47,994	23,604	9,355
Other research and development expenses
Other research and development expenses
Infrastructure expenses	1,200	1,300	1,400
Advisory and external consultancy expenses	1,200	900	700
Intellectual property and trademark related expenses	500	400	700
Travel expenses	400	400	200
Other expenses	$ 100	$ 100	$ 100

General and Administrative Ex68

General and Administrative Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
General and Administrative Expenses
Depreciation and amortisation	$ 233	$ 153	$ 166
Total	13,535	7,921	3,739
General and administrative expenses
General and Administrative Expenses
Other general and administrative expenses	7,915	4,378	2,232
Staff costs	5,521	3,491	1,463
Depreciation and amortisation	99	52	44
Total	13,535	7,921	3,739
Other general and administrative expenses
Other general and administrative expenses
Advisory and external consultancy expenses	2,400	1,300	500
Tax consulting, payroll accounting, accounting and auditing expenses	1,100	700	500
Infrastructure expenses	1,400	700	500
Legal expenses	1,000	500	300
Travel expenses	300	300	100
Supervisory board fees and expenses	400	200	100
Other expenses	$ 1,300	$ 700	$ 200

Post-employment benefit oblig69

Post-employment benefit obligations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Austria
Monthly contribution (as a percent)	1.53%	1.53%	1.53%
Contribution costs	$ 59	$ 58	$ 65
U.S.
Contribution costs	$ 157	$ 57	$ 4
Percent of match, first level	100.00%	100.00%	100.00%
Employee voluntary contribution, first level	3.00%	3.00%	3.00%
Percent match, second level	50.00%	50.00%	50.00%
Employee voluntary contribution, second level	2.00%	2.00%	2.00%

Other income (expense), net (De

Other income (expense), net (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Other income (expense), net
Foreign exchange gain									$ 2,444	$ 3,309	$ 6
Foreign exchange losses									(3,282)	(476)	(15)
Other									55	(406)	(515)
Total	$ (1,118)	$ 107	$ (590)	$ 1,086	$ 2,071	$ (347)	$ (18,997)	$ (2,378)	$ (783)	$ 2,427	$ (524)

Income tax (expense) benefit (D

Income tax (expense) benefit (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income (loss) before income taxes attributable to domestic and international operations
Domestic									$ (54,509)	$ (46,300)	$ (14,163)
Foreign									(1,053)	(1,109)	35
Loss before income taxes									(55,562)	(47,409)	(14,128)
Current tax
Domestic									(4)	(3)	(78)
Foreign									(118)	(172)	(5)
Deferred tax
Foreign									794	620	(11)
Income tax (expense) benefit	$ 671	$ (28)	$ 12	$ 17	$ 205	$ 254	$ (2)	$ (12)	$ 672	$ 445	$ (94)
Effective income tax reconciliation
Austria statutory income tax rate									25.00%	25.00%	25.00%
Non-deductible expenses									(0.20%)	(0.10%)	(0.20%)
Income not subject to tax									2.80%	1.90%	2.40%
Tax credits									0.40%	0.00%	0.00%
Foreign rate differential									0.20%	0.20%	0.00%
Other									0.20%	0.20%	0.00%
Valuation allowance									(27.20%)	(26.30%)	(27.90%)
Effective income tax rate									1.20%	0.90%	(0.70%)

Income tax (expense) benefit -

Income tax (expense) benefit - Deferred income taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Net operating loss carryforwards	$ 54,220	$ 40,616
Equity compensation	1,025	382
Non-deductible reserves	409	256
Total deferred tax assets	55,654	41,254
Valuation allowance	(54,114)	(40,487)
Net deferred tax assets	1,540	767
Deferred tax liabilities:
Financial liabilities	95	123
Property, plant and equipment	35	28
Total deferred tax liability	130	151
Deferred tax, net	$ 1,410	$ 616

Income tax (expense) benefit 73

Income tax (expense) benefit - Valuation Allowance (Details) - Deferred Tax Valuation Allowance - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of year	$ (40,487)	$ (30,507)	$ (29,484)
Charges to costs and expenses	(13,627)	(9,980)	(1,023)
Balance at ending of year	$ (54,114)	$ (40,487)	$ (30,507)

Income tax (expense) benefit 74

Income tax (expense) benefit - NOL and Uncertain Tax Positions (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Net operating loss carryforwards
Net operating loss carryforwards	$ 216.9	$ 162.5
Uncertain tax positions disclosures
Uncertain tax positions	$ 0	$ 0

Earnings (Loss) per Share (Deta

Earnings (Loss) per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Basic earnings/losses per share
Net loss	$ (15,187)	$ (14,000)	$ (12,104)	$ (13,599)	$ (7,965)	$ (8,420)	$ (24,520)	$ (6,059)	$ (54,890)	$ (46,964)	$ (14,222)
Adjustment to redemption value										(3,875)	(192)
Net loss attributable to shareholders									$ (54,890)	$ (50,839)	$ (14,414)
Weighted average number of shares outstanding									2,147,832	1,058,395	324,703
Excluded treasury shares on December 31										2,819	2,819
Basic loss per share	$ (6.84)	$ (6.58)	$ (5.70)	$ (6.42)	$ (3.79)	$ (7.46)	$ (37.54)	$ (30.60)	$ (25.56)	$ (48.03)	$ (44.39)
Antidilutive share options
Number of outstanding share options excluded from computation of diluted earnings per share									190,432	132,706	24,133
Diluted earnings/losses per share
Net loss	$ (15,187)	$ (14,000)	$ (12,104)	$ (13,599)	$ (7,965)	$ (8,420)	$ (24,520)	$ (6,059)	$ (54,890)	$ (46,964)	$ (14,222)
Adjustment to redemption value										(3,875)	(192)
Loss used to determine dilutive earnings per share									$ (54,890)	$ (50,839)	$ (14,414)
Weighted average number of shares outstanding									2,147,832	1,058,395	324,703
Weighted average number of shares for diluted earnings (loss) per share									2,147,832	1,058,395	324,703
Diluted loss per share	$ (6.84)	$ (6.58)	$ (5.70)	$ (6.42)	$ (3.79)	$ (7.46)	$ (37.54)	$ (30.60)	$ (25.56)	$ (48.03)	$ (44.39)

Property, Plant and Equipment76

Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment
Property, plant and equipment, gross	$ 3,270	$ 2,963
Less: Accumulated depreciation	(2,751)	(2,546)
Property, plant and equipment, net	519	417
IT equipment
Property, Plant and Equipment
Property, plant and equipment, gross	642	490
Laboratory appliances
Property, Plant and Equipment
Property, plant and equipment, gross	2,613	2,458
Other equipment
Property, Plant and Equipment
Property, plant and equipment, gross	$ 15	$ 15

Fair Value Measurement (Details

Fair Value Measurement (Details) - USD ($) $ in Thousands	May 13, 2015	Dec. 31, 2015	Dec. 31, 2016
Short-term investments:
Transfer of assets from Level 1 to 2		$ 0	$ 0
Transfer of assets from Level 2 to 1		0	0
Transfer of liabilities from Level 1 to 2		0	0
Transfer of liabilities from Level 2 to 1		0	0
Reconciliation of Level 3 fair value measurements of financial liabilities:
Opening balance		3,203
Total (gains) losses in profit or loss		144
Settlement by issued equity instruments		(1,420)
Waiver of option rights		(1,585)
Fx differences		(342)
Recurring
Short-term investments:
Available-for-sale investments		29,969	51,076
Term Deposits		45,025	30
Total Assets		74,994	51,106
Kreos Capital IV
Reconciliation of Level 3 fair value measurements of financial liabilities:
Exercise of options	$ 1,420	1,420
Level 1 | Recurring
Short-term investments:
Available-for-sale investments		9,967	15,017
Term Deposits		45,025	30
Total Assets		54,992	15,047
Level 2 | Recurring
Short-term investments:
Available-for-sale investments		20,002	36,059
Total Assets		$ 20,002	$ 36,059

Long-term and current receiva78

Long-term and current receivables (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Long-term receivables
Deposits	$ 420,000	$ 430,000
Total long-term receivables	420,000	430,000
Current receivables
Research premium	5,346,000	3,527,000
VAT and other taxes	46,000	450,000
Receivables from grant revenue	144,000
Other receivables	25,000	218,000
Total current receivables	5,561,000	4,195,000
Total long-term and current receivables	5,981,000	4,625,000
Receivables additional disclosures
Past due receivables	0
Impaired receivables	0	0
Pledged receivables	$ 0	$ 0

Short-term investments (Details

Short-term investments (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Short-term investments
Amortized Cost	$ 51,124	$ 75,062
Unrealized Losses	(18)	(68)
Fair Value	51,106	74,994
Available-for-sale investments
Short-term investments
Amortized Cost	51,094	30,037
Unrealized Losses	(18)	(68)
Fair Value	51,076	29,969
Term deposits
Short-term investments
Amortized Cost	30	45,025
Fair Value	$ 30	$ 45,025

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash and Cash Equivalents
Cash at bank	$ 32,778	$ 36,446
Total cash and cash equivalents	$ 32,778	$ 36,446	$ 2,150	$ 4,957

Share-Based Payments - Stock Op

Share-Based Payments - Stock Option Plan 2007 (Details) - Stock Option Plan 2007 - USD ($) $ / shares in Units, $ in Thousands	Aug. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Sep. 12, 2007
Share-Based Payments
Number of awards that can be granted					29,889
Vested option rights outstanding		$ 2,016	$ 4,200	$ 4,253
Weighted average exercise price in $ per share
Outstanding balance at beginning of year (in dollars per share)		$ 7.32	$ 7.32	$ 7.32
Granted (in dollars per share)				7.32
Exercised (in dollars per share)		7.32	7.32
Forfeited (in dollars per share)		7.32
Outstanding balance at end of year (in dollars per share)		7.32	7.32	$ 7.32
Vested and exercisable balance at end of year (in dollars per share)		$ 7.32	$ 7.32
Options
Outstanding at beginning of year (in shares)		23,476	24,133	23,045
Granted (in shares)	1,088			1,088
Exercised (in shares)		(12,454)	(657)
Forfeited (in shares)		(26)
Outstanding at end of year (in shares)		10,996	23,476	24,133
Vested and exercisable at end of year (in shares)		10,790	22,927
Aggregate Intrinsic value
Outstanding at end of year (in dollars)		$ 2,056
Vested and exercisable at end of year (in dollars)		2,013
Total intrinsic value of options exercised		$ 2,246	$ 119
Other disclosures
Weighted-average remaining contractual life		4 months 24 days
Weighted-average grant date fair value (in dollars per share)				$ 209.11
Share-based compensation expense (in dollars)		$ 95	$ 78	$ 96
Weighted average of share price at the date of exercise of options (in dollars per share)		$ 77.70	$ 86.60
Options
Share-Based Payments
Vesting period		4 years
Minimum percentage of shares or asset sale to permit exercise		50.00%
Fair Value Assumptions
Expected volatility (as a percent)	65.00%
Expected option term (in years)	1 year 3 months 18 days
Risk-free interest rate (as a percent)	0.03%
Options | First year
Share-Based Payments
Vesting period		1 year
Percentage that vests during the period		25.00%
Options | Second year
Share-Based Payments
Vesting period		2 years
Percentage that vests during the period		25.00%
Options | Third and fourth years
Share-Based Payments
Vesting period		4 years
Percentage that vests during the period		50.00%
Monthly vesting percentage		2.083%

Share-Based Payments - Stock 82

Share-Based Payments - Stock Option Plan 2015 (Details) - Stock Option Plan 2015 - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Aug. 25, 2016	Sep. 23, 2015	Apr. 02, 2015
Share-Based Payments
Number of awards that can be granted				346,235	177,499	95,000
Exercise period	10 years
Vested option rights outstanding	$ 3,543	$ 1,274	$ 0
Weighted average exercise price in $ per share
Outstanding balance at beginning of year (in dollars per share)	$ 76.10
Granted (in dollars per share)	80.24	$ 76.09
Exercised (in dollars per share)	72.05
Forfeited (in dollars per share)	76.35	72.05
Outstanding balance at end of year (in dollars per share)	78.25	76.10
Vested and exercisable balance at end of year (in dollars per share)	$ 75.17	$ 72.05
Options
Outstanding at beginning of year (in shares)	109,230
Granted (in shares)	92,213	109,355
Exercised (in shares)	(2,336)
Forfeited (in shares)	(19,671)	(125)
Outstanding at end of year (in shares)	179,436	109,230
Vested and exercisable at end of year (in shares)	42,521	8,662
Aggregate Intrinsic value
Outstanding at end of year (in dollars)	$ 9,249
Vested and exercisable at end of year (in dollars)	3,043
Total intrinsic value of options exercised	$ 181
Options
Share-Based Payments
Vesting period	4 years
Options | First year
Share-Based Payments
Vesting period	1 year
Percentage that vests during the period	25.00%
Options | Second, third and fourth years
Share-Based Payments
Vesting period	4 years
Percentage that vests during the period	75.00%
Monthly vesting percentage	2.083%

Share-Based Payments - Stock 83

Share-Based Payments - Stock Option Plan 2015 Outstanding and Fair Value (Details) - Stock Option Plan 2015 - USD ($) $ / shares in Units, $ in Thousands	Dec. 31, 2015	Nov. 30, 2015	Oct. 31, 2015	Sep. 30, 2015	Jul. 15, 2015	Dec. 31, 2016	Dec. 31, 2015
Share-Based Payments
Outstanding	109,230					179,436	109,230
Outstanding options exercise price (in dollars per share)	$ 76.10					$ 78.25	$ 76.10
Share-based compensation expense (in dollars)						$ 2,450	$ 1,274
Income tax benefit						$ 643	$ 382
Weighted-average grant date fair value (in dollars per share)						$ 30.58	$ 70.72
Fair Value Assumptions
Exercise price (in dollars per share)						$ 80.24	$ 76.09
Other disclosures
Weighted-average remaining contractual life						9 years 2 months 12 days	9 years 7 months 6 days
Granted on July 6, 2015
Share-Based Payments
Outstanding	91,780					77,990	91,780
Outstanding options exercise price (in dollars per share)						$ 72.05
Granted on September 30, 2015
Share-Based Payments
Outstanding	11,000					11,000	11,000
Outstanding options exercise price (in dollars per share)						$ 95
Granted on October 31, 2015
Share-Based Payments
Outstanding	750					750	750
Outstanding options exercise price (in dollars per share)						$ 99.50
Granted on November 30, 2015
Share-Based Payments
Outstanding	5,500					5,500	5,500
Outstanding options exercise price (in dollars per share)						$ 101.90
Granted on December 31, 2015
Share-Based Payments
Outstanding	200					200	200
Outstanding options exercise price (in dollars per share)						$ 96.20
Granted on January 31, 2016
Share-Based Payments
Outstanding						750
Outstanding options exercise price (in dollars per share)						$ 84.70
Granted on February 5, 2016
Share-Based Payments
Outstanding						55,771
Outstanding options exercise price (in dollars per share)						$ 83.40
Granted on March 31, 2016
Share-Based Payments
Outstanding						75
Outstanding options exercise price (in dollars per share)						$ 89.60
Granted on April 30, 2016
Share-Based Payments
Outstanding						75
Outstanding options exercise price (in dollars per share)						$ 85
Granted on May 31, 2016
Share-Based Payments
Outstanding						9,955
Outstanding options exercise price (in dollars per share)						$ 72.50
Granted on June 30, 2016
Share-Based Payments
Outstanding						3,000
Outstanding options exercise price (in dollars per share)						$ 75
Granted on July 31, 2016
Share-Based Payments
Outstanding						325
Outstanding options exercise price (in dollars per share)						$ 84.30
Granted on August 26,2016
Share-Based Payments
Outstanding						12,120
Outstanding options exercise price (in dollars per share)						$ 74.90
Granted on August 31, 2016
Share-Based Payments
Outstanding						75
Outstanding options exercise price (in dollars per share)						$ 79.80
Granted on September 30, 2016
Share-Based Payments
Outstanding						500
Outstanding options exercise price (in dollars per share)						$ 70.50
Granted on October 31, 2016
Share-Based Payments
Outstanding						1,000
Outstanding options exercise price (in dollars per share)						$ 57.30
Granted on November 30, 2016
Share-Based Payments
Outstanding						350
Outstanding options exercise price (in dollars per share)						$ 40.60
Options
Other disclosures
Total unrecognized compensation related to non-vested options (in dollars)						$ 5,701
Period of recognition of total unrecognized compensation related to options						2 years 2 months 12 days
Options | Granted on July 6, 2015
Fair Value Assumptions
Grant date share price (in dollars per share)					$ 160
Exercise price (in dollars per share)					$ 72.05
Expected volatility (as a percent)					55.00%
Expected option term (in years)					2 years
Risk-free interest rate (as a percent)					(0.21%)
Options | Granted on September 30, 2015
Fair Value Assumptions
Grant date share price (in dollars per share)				$ 95
Exercise price (in dollars per share)				$ 95
Expected volatility (as a percent)				70.00%
Expected option term (in years)				2 years 2 months 12 days
Risk-free interest rate (as a percent)				(0.231%)
Options | Granted on October 31, 2015
Fair Value Assumptions
Grant date share price (in dollars per share)			$ 99.50
Exercise price (in dollars per share)			$ 99.50
Expected volatility (as a percent)			70.00%
Expected option term (in years)			2 years 2 months 12 days
Risk-free interest rate (as a percent)			(0.307%)
Options | Granted on November 30, 2015
Fair Value Assumptions
Grant date share price (in dollars per share)		$ 101.90
Exercise price (in dollars per share)		$ 101.90
Expected volatility (as a percent)		70.00%
Expected option term (in years)		2 years 2 months 12 days
Risk-free interest rate (as a percent)		(0.40%)
Options | Granted on December 31, 2015
Fair Value Assumptions
Grant date share price (in dollars per share)	$ 96.20						$ 96.20
Exercise price (in dollars per share)	$ 96.20
Expected volatility (as a percent)	70.00%
Expected option term (in years)	2 years 3 months 18 days
Risk-free interest rate (as a percent)	(0.323%)

Share-Based Payments - Founders

Share-Based Payments - Founders' Program 2007 (Details) - Founder's Program 2007 - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		12 Months Ended				24 Months Ended
	Feb. 29, 2008	Nov. 30, 2007	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2007	Feb. 28, 2010
Share-Based Payments
Outstanding			623
Outstanding options exercise price (in dollars per share)			$ 1
Percentage that vests during the period	25.00%	25.00%					50.00%
Vested (in shares)	155	156
Monthly vesting percentage							2.083%
Shares vested monthly (in shares)							13
Weighted-average grant date fair value (in dollars per share)						$ 144.23
Vested option rights outstanding			$ 122	$ 122	$ 122
Forfeited (in shares)			0	0	0
Exercise of options (in shares)			0	0	0

April 2015 Financing (Details)

April 2015 Financing (Details) € / shares in Units, $ / shares in Units, $ in Thousands, € in Millions	1 Months Ended		12 Months Ended
	Apr. 30, 2015EUR (€)€ / sharesshares	Apr. 30, 2015USD ($)shares	Dec. 31, 2016shares	Dec. 31, 2015USD ($)shares	Sep. 30, 2015€ / sharesshares	Apr. 30, 2015USD ($)tranche$ / shares
Financing
Shares issued price per share | € / shares					€ 1
Proceeds from April 2015 financing	€ 42.1			$ 44,836
Common Stock
Financing
Number of shares sold			588,000	1,563,000
Shares issued in exchange for the conversion of convertible loans and silent partnerships investments				204,000
April 2015 Financing
Financing
Number of tranches in the sale of shares | tranche						2
Number of shares sold	730,162	730,162
Number of shares issued for cash consideration	511,188	511,188
Shares issued price per share | $ / shares						$ 87.71
Proceeds from April 2015 financing | $		$ 44,836
Shares issued in exchange for the conversion of convertible loans and silent partnerships investments	218,974	218,974
Aggregate purchase price of shares to be sold in the second tranche | $						$ 70,000
Preferential right to acquire additional shares (in dollars per share) | € / shares	€ 1
Preferred dividend rate (as a percent)	8.00%	8.00%
Proceeds from April 2015 financing and the related conversion of outstanding convertible loan agreements and silent partnership interests | $		$ 77,300
Number of shares issued for each preferred dividend right					17,149
April 2015 Financing | Common Stock
Financing
Number of shares sold				15,000

December 2016 Financing (Detail

December 2016 Financing (Details) $ / shares in Units, $ in Thousands	Dec. 19, 2016USD ($)shares	Dec. 14, 2016€ / sharesshares	Sep. 23, 2015shares	Dec. 31, 2016USD ($)shares	Dec. 31, 2015shares	Dec. 19, 2016€ / sharesshares	Dec. 19, 2016$ / sharesshares	Sep. 30, 2015€ / shares
Financing
Gross proceeds from sale of shares | $				$ 24,822
Number of common shares represented by each ADS share			0.1
Shares issued price per share | € / shares								€ 1
Common Stock
Financing
Number of shares sold				588,000	1,563,000
December 2016 Financing
Financing
Aggregate ADS shares subscribed for by holders of ADS	1,592,750
Aggregate number of common shares represented by the aggregate ADS shares subscribed for by holders of ADS	159,275
Number of common shares represented by each ADS share	0.1
Aggregate number of common shares subscribed for by holders of common shares	102,077
December 2016 Financing | ADS | ADS Right
Financing
Number of rights into which each share of stock converted	0.276
Number of shares into which each right was entitled						1	1
Per share exercise price of right | (per share)						€ 4.014	$ 4.32
December 2016 Financing | Common Stock
Financing
Number of shares sold	588,127
Gross proceeds from sale of shares | $	$ 24,800
Net proceeds from sale of shares, after deducting underwriting fees and offering expenses | $	$ 20,600
December 2016 Financing | Common Stock | Common Share Right
Financing
Number of shares into which each right was entitled						0.276	0.276
Per share exercise price of right | € / shares						€ 40.14
December 2016 Financing Underwriting | Common Stock
Financing
Number of shares sold		326,775
Shares issued price per share | € / shares		€ 40.14

Investment from Silent Partne87

Investment from Silent Partnership (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Investment from Silent Partnership
Carrying amount as of beginning of year	$ 634
Issuance (net of $150 transaction costs)	962	$ 552
Recognition of beneficial conversion features	(2,561)	(36)
Adjustment to redemption value	3,875	192
Settlement by issued equity instruments	(2,750)
Fx differences	(160)	(74)
Carrying amount as of end of year		$ 634
Transaction costs	$ 150

Kreos Loan 2014 - Terms (Detail

Kreos Loan 2014 - Terms (Details) - Kreos Loan 2014 € in Thousands, $ in Thousands	Jul. 04, 2014EUR (€)	Jul. 04, 2014USD ($)	Jun. 30, 2014EUR (€)
Kreos Loan 2014
Loan amount		$ 6,643	€ 5,000
Minimum book value of fixed assets pledged as collateral for loan | €	€ 1,000
Carrying amount at which the loan may be prepaid		3,462
Call Options
Kreos Loan 2014
Amount used in calculation for number of shares to be issued upon exercise		$ 996
Percentage of loan represented by the dollar amount used in the shares calculation		15.00%

Kreos Loan 2014 - Movement (Det

Kreos Loan 2014 - Movement (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Movement in carrying amount
Interest paid	$ (41)	$ (1,057)	$ (553)
Kreos Loan 2014
Movement in carrying amount
Carrying amount at beginning of period		$ 4,992
Effective interest accrued	942
Interest paid	(511)
Monthly installments	(1,883)
Early repayment	(3,462)
Loss on early extinguishment of debt	496
Fx differences	$ (574)
Carrying amount at end of period			$ 4,992

Kreos Loan 2014 - Option Exerci

Kreos Loan 2014 - Option Exercise (Details) - Kreos Capital IV - USD ($) $ / shares in Units, $ in Thousands	May 13, 2015	Dec. 31, 2015
Kreos Loan 2014
Call option rights exercised (in shares)	9,107
Conversion price upon exercise (in dollars per share)	$ 87.71
Value of the call options reclassified to equity	$ 1,420	$ 1,420

Convertible Loans - Terms (Deta

Convertible Loans - Terms (Details) $ / shares in Units, $ in Thousands	Jan. 08, 2015USD ($)	Apr. 30, 2015$ / shares	Mar. 31, 2015USD ($)agreementitem$ / sharesshares	Dec. 31, 2015USD ($)
Convertible Loans
Increase in value of conversion options related to extension of repayment dates | $				$ 738
Convertible Loan Agreements
Convertible Loans
Number of CLAs | agreement			5
Amount | $			$ 18,172
Conversion Price (in dollars per share) | $ / shares			$ 247.54
Minimum external equity financing for conversion price to be adjusted | $			$ 5,000
Increase in value of conversion options related to extension of repayment dates | $	$ 738			$ 738
Conversion price as adjusted for equity financing (in dollars per share) | $ / shares		$ 87.71
CLA1
Convertible Loans
Amount | $			$ 8,664
Interest Rate (as a percent)			7.73%
Conversion Price (in dollars per share) | $ / shares			$ 247.54
CLA1 | Call Options
Convertible Loans
Additional Call Options - Number (in shares) | shares			7,000
Additional Call Options - Exercise Price (in dollars per share) | $ / shares			$ 247.54
CLA2
Convertible Loans
Amount | $			$ 685
Conversion Price (in dollars per share) | $ / shares			$ 247.54
Early repayment premium as multiple of principal amount | item			1
CLA2 | Call Options
Convertible Loans
Additional Call Options - Number (in shares) | shares			554
Additional Call Options - Exercise Price (in dollars per share) | $ / shares			$ 247.54
CLA3
Convertible Loans
Amount | $			$ 3,303
Interest Rate (as a percent)			7.73%
Conversion Price (in dollars per share) | $ / shares			$ 247.54
CLA4
Convertible Loans
Amount | $			$ 2,166
Interest Rate (as a percent)			7.73%
Conversion Price (in dollars per share) | $ / shares			$ 247.54
CLA5
Convertible Loans
Amount | $			$ 3,354
Interest Rate (as a percent)			7.73%
Conversion Price (in dollars per share) | $ / shares			$ 247.54

Convertible Loans - Movement (D

Convertible Loans - Movement (Details) - USD ($) $ in Thousands	Jan. 08, 2015	Dec. 31, 2015	Dec. 31, 2014
Movements in CLAs
Extension of CLA repayment date - Modification		$ (738)
Recognition of beneficial conversion features		(18,993)	$ (526)
Convertible Loan Agreements
Movements in CLAs
Carrying amount at beginning of period		19,365
Proceeds of issue		3,588
Extension of CLA repayment date - Modification	$ (738)	(738)
Recognition of beneficial conversion features		(18,993)
Interest expense recognized		20,514
Waiving of interest		(2,842)
Settlement by issued equity instruments		(18,314)
Fx differences		$ (2,580)
Carrying amount at end of period			$ 19,365

Accrued Expenses and Other Li93

Accrued Expenses and Other Liabilities - Obligation (Details) - Collective bargaining arrangement, Chemical industry - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Principle actuarial assumptions used in calculation of the company's obligations for jubilee payments
Discount rate	1.30%	2.00%
Annual salary increase rate	3.00%
Minimum
Principle actuarial assumptions used in calculation of the company's obligations for jubilee payments
Retirement age for men (in years)	61 years 6 months
Retirement age for women (in years)	56 years 6 months
Maximum
Principle actuarial assumptions used in calculation of the company's obligations for jubilee payments
Retirement age for men (in years)	65 years
Retirement age for women (in years)	65 years
Other non-current liabilities
Other non-current liabilities
Provision for jubilee payments obligation	$ 107	$ 84

Accrued Expenses and Other Li94

Accrued Expenses and Other Liabilities - Accrued expenses and other current liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Components of accrued expenses and other current liabilities:
Research and development related costs	$ 8,716	$ 3,329
Payroll and related costs	2,150	1,669
Accounting, tax and audit services	484	272
Other	1,958	553
Total other current liabilities	$ 13,308	$ 5,823

Commitments and Contingencies -

Commitments and Contingencies - Lease Arrangements (Details) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Dec. 31, 2014	Dec. 31, 2007	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Lease Arrangements
Rent expense			$ 1,263	$ 861	$ 858
Obligations payable under the lease agreement:
No later than 1 year			1,484	1,576
Later than 1 year and no later than 5 years			2,536	3,494
Later than 5 years			507	1,030
Total			4,527	6,100
Lease agreement for use of business and research premises at Vienna
Lease Arrangements
Term of the lease agreement, under which it can only be terminated under certain conditions		10 years
Monthly costs for facility management and security services			9	9	11
Lease agreement for use of business and research premises at Vienna | Premises and laboratory furniture
Lease Arrangements
Monthly rent			85	84	$ 101
Lease agreement for use of office premises at King of Prussia, Suite 450
Lease Arrangements
Monthly rent			9	9
Term of the lease agreement	2 years
Lease agreement for use of office premises at King of Prussia, Suite 600
Lease Arrangements
Monthly rent			$ 40	$ 39

Commitments and Contingencies96

Commitments and Contingencies - Other contractual commitments and Contingencies (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Remaining payments to be made under other contractual agreements
No later than 1 year	$ 51,685	$ 21,293
Later than 1 year and no later than 5 years	6,241	19,679
Total	57,926	$ 40,972
Contingencies
Contingent liabilities	$ 0

Related Parties (Details)

Related Parties (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Mar. 31, 2015USD ($)agreement
Convertible Loan Agreements
Related Parties
Aggregate principal amount				$ 18,172
Number of CLAs | agreement				5
Talbot Advisors LLC, of which George Talbot is Principal
Related Parties
Payment for services	$ 4,500	$ 17,400	$ 163,900

Selected Quarterly Financial 98

Selected Quarterly Financial Information (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Selected Quarterly Financial Information (Unaudited)
Revenues	$ 2,307	$ 971	$ 1,785	$ 1,419	$ 974	$ 1,297	$ 899	$ 597	$ 6,482	$ 3,767	$ 2,398
Operating expenses	(17,047)	(15,050)	(13,311)	(16,121)	(11,215)	(9,624)	(6,420)	(4,266)	(61,529)	(31,525)	(13,094)
Loss from operations	(14,740)	(14,079)	(11,526)	(14,702)	(10,241)	(8,327)	(5,521)	(3,669)	(55,047)	(27,758)	(10,696)
Other income (expense), net	(1,118)	107	(590)	1,086	2,071	(347)	(18,997)	(2,378)	(783)	2,427	(524)
Income tax (expense) benefit	671	(28)	12	17	205	254	(2)	(12)	672	445	(94)
Net loss	$ (15,187)	$ (14,000)	$ (12,104)	$ (13,599)	$ (7,965)	$ (8,420)	$ (24,520)	$ (6,059)	$ (54,890)	$ (46,964)	$ (14,222)
Basic loss per share	$ (6.84)	$ (6.58)	$ (5.70)	$ (6.42)	$ (3.79)	$ (7.46)	$ (37.54)	$ (30.60)	$ (25.56)	$ (48.03)	$ (44.39)
Diluted loss per share	$ (6.84)	$ (6.58)	$ (5.70)	$ (6.42)	$ (3.79)	$ (7.46)	$ (37.54)	$ (30.60)	$ (25.56)	$ (48.03)	$ (44.39)